Document:

INDEMNIFICATION
AGREEMENT

 

THIS INDEMNIFICATION
AGREEMENT (this "Agreement") is made and entered into this 31st day of January, 2013, by and between VRINGO,
INC., a Delaware corporation (the "Corporation"), and ________________ ("Agent").

 

RECITALS

 

WHEREAS, Agent
performs a valuable service to the Corporation in his capacity as _________ of the Corporation;

 

WHEREAS, the
Corporation has adopted provisions providing for indemnification of directors and officers included in its Amended and Restated
Certificate of Incorporation (the "Charter") and its Amended and Restated Bylaws (the "Bylaws")
providing for the indemnification of the directors, officers, employees and other agents of the Corporation, including persons
serving at the request of the Corporation in such capacities with other corporations or enterprises, as authorized by the Delaware
General Corporation Law, as amended (the "DGCL");

 

WHEREAS, the
Charter, the Bylaws and the DGCL, by their non-exclusive nature, permit contracts between the Corporation and its directors, officers,
employees and other agents with respect to indemnification of such persons;

 

WHEREAS, in
recognition of Agent's need for (a) substantial protection against personal liability based on Agent's reliance on the Charter
and the Bylaws, and (b) specific contractual assurance that the protection provided in the Charter and the Bylaws will be available
to Agent (regardless of, among other things, any amendment to or revocation of the Charter and/or the Bylaws, any change in the
composition of the Corporation's board of directors or a change in control of the Corporation);

 

WHEREAS, in
order to induce Agent to continue to serve as [a director/an officer] of the Corporation, the Corporation has determined and agreed
to enter into this Agreement with Agent; and

 

WHEREAS, this
Agreement supersedes and replaces the indemnification provisions set forth in any employment agreement between the Corporation
and the Agent.

 

NOW, THEREFORE,
in consideration of Agent's service as an officer of the Corporation following the date hereof, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Corporation and Agent hereby agree as follows:

 

1.            Services
to the Corporation. Agent will serve, at the will of the Corporation (subject
to any contractual obligation that Corporation may have assumed apart from this Agreement) or under separate contract,
if any such contract exists, as an officer of the Corporation or as a director, officer or other fiduciary of an affiliate of
the Corporation (including any employee benefit plan of the Corporation) in a manner consistent with his fiduciary duties so long
as he is duly elected and qualified in accordance with the provisions of the Bylaws or other applicable charter documents/is a
duly appointed officer of the Corporation or such affiliate; provided, however, that Agent may at any time and for any reason
resign from such position (subject to any contractual obligation that Agent may have assumed apart from this Agreement) and that
the Corporation or any affiliate shall have no obligation under this Agreement to continue Agent in any such position.

 

    	 

    	 

    

 

2.            Indemnity
of Agent. The Corporation agrees to hold harmless and indemnify Agent to the fullest extent authorized or permitted by the
provisions of the Charter, the Bylaws and the DGCL, as the same may be amended from time to time (but, only to the extent that
such amendment permits the Corporation to provide broader indemnification rights than the Charter, the Bylaws or the DGCL permitted
prior to adoption of such amendment).

 

3.            Additional
Indemnity. In addition to and not in limitation of the indemnification otherwise provided for herein, and subject only to
the exclusions set forth in Section 4 hereof, the Corporation further agrees to hold harmless and indemnify Agent:

 

(a)          against
any and all expenses (including attorneys' fees), witness fees, damages, judgments, fines and amounts paid in settlement and any
other amounts that Agent becomes legally obligated to pay (including any federal, state or local taxes imposed on Agent as a result
of receipt of reimbursements or advances of expenses under this Agreement) because of any claim or claims made against or by him
in connection with any threatened, pending or completed action, suit or proceeding, including any appeal and the premium, security
for, and other costs relating to any costs bond, supersedes bond, or other appeal bond or its equivalent, whether civil, criminal,
arbitrational, administrative or investigative, whether formal or informal (including an action by or in the right of the Corporation),
to which Agent is, was or at any time becomes a party or a witness, or is threatened to be made a party or a witness, by reason
of the fact that Agent is, was or at any time becomes a director, officer, employee or other agent of the Corporation, or is or
was serving or at any time serves at the request of the Corporation as a director, officer, employee or other agent of another
corporation, partnership, joint venture, trust, employee benefit plan or other enterprise; and

 

(b)          otherwise
to the fullest extent as may be provided to Agent by the Corporation under the non-exclusivity provisions of the DGCL, the Charter
and the Bylaws.

 

4.            Limitations
on Additional Indemnity. No indemnity pursuant to Section 3 hereof shall be paid by the Corporation: 

 

(a)          on
account of any claim or proceeding against Agent for an accounting of profits made from the purchase or sale by Agent of securities
of the Corporation pursuant to the provisions of Section 16(b) of the Securities Exchange Act of 1934, as heretofore or hereafter
amended (the "Exchange Act"), or similar provisions of any federal, state or local law, provided, however, if
and when Agent ultimately establishes in any such proceeding that no recovery of profits from Agent is permitted under Section
16(b) of the Exchange Act or such similar provision of any similar federal, state or local law, then, notwithstanding anything
to the contrary provided in this Section 4(a), indemnification pursuant to this Agreement shall then be permitted;

 

    	2

    	 

    

 

(b)          on
account of Agent's conduct that is established by a final judgment as knowingly fraudulent or deliberately dishonest or that constituted
willful misconduct;

 

(c)          on
account and to the extent of Agent's conduct that is established by a
final judgment as constituting a breach of Agent's duty of loyalty to the Corporation or resulting in any personal profit or advantage
to which Agent was not legally entitled;

 

(d)          on
account and to the extent of any payment which is actually made to Agent under any valid and collectible insurance policy or under
any valid and enforceable indemnity clause, bylaw or agreement, except to the extent of any excess indemnifiable amounts not covered
under such insurance, clause, bylaw or;

 

(e)          to
the extent indemnification is prohibited by applicable law (and, in this respect, both the Corporation and Agent have been advised
that the Securities and Exchange Commission believes that indemnification for liabilities arising under the federal securities
laws is against public policy and is, therefore, unenforceable and that claims for indemnification should be submitted to appropriate
courts for adjudication). Both the Corporation and Agent acknowledge
that, in certain instances, federal law or applicable public policy may prohibit the Company from indemnifying, exonerating or
holding harmless its directors, officers, employees, agents or fiduciaries under this Agreement or otherwise. The Agent understands
and acknowledges that the Corporation may be required in the future to undertake with the Securities and Exchange Commission to
submit the question of indemnification, exoneration or hold harmless rights to a court in certain circumstances for a determination
of the Corporation's right under public policy to indemnify, exonerate or hold harmless the Agent.; or

 

(f)          in
connection with any proceeding (or part thereof) initiated by Agent, or any proceeding by Agent against the Corporation or its
directors, officers, employees or other agents, unless (i) such indemnification is expressly required to be made by law, (ii)
the proceeding was authorized by the board of directors of the Corporation, (iii) such indemnification is provided by the Corporation,
in its sole discretion, pursuant to the powers vested in the Corporation under the DGCL, or (iv) the proceeding is initiated pursuant
to Section 11 hereof.

 

5.            Continuation
of Indemnity. All agreements and obligations of the Corporation contained herein shall continue during the period Agent is
a director, officer, employee or other agent of the Corporation (or is or was serving at the request of the Corporation as a director,
officer, employee or other agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise)
and shall continue thereafter so long as Agent shall be subject to any possible claim or threatened, pending or completed action,
suit or proceeding, whether civil, criminal, arbitrational, administrative or investigative, by reason of the fact that Agent
was serving in the capacity referred to herein. 

 

6.            Partial
Indemnification. Agent shall be entitled under this Agreement to indemnification by the Corporation for a portion of the expenses
(including attorneys' fees), witness fees, damages, judgments, fines and amounts paid in settlement and any other amounts that
Agent becomes legally obligated to pay in connection with any action, suit or proceeding referred to in Section 3 hereof even
if not entitled hereunder to indemnification for the total amount thereof, and the Corporation shall indemnify Agent for the portion
thereof to which Agent is entitled.

 

    	3

    	 

    

 

7.            Notification
and Defense of Claim. As soon as practicable, and in any event, not later than thirty (30) days after Agent becomes aware,
by written or other overt communication, of any pending or threatened litigation, claim or assessment, Agent will, if a claim
in respect thereof is to be made against the Corporation under this Agreement, notify the Corporation of such pending or threatened
litigation, claim or assessment; but the omission so to notify the Corporation will not relieve it from any liability which it
may have to Agent otherwise than under this Agreement. With respect to any such pending or threatened litigation, claim or assessment
as to which Agent notifies the Corporation of the commencement thereof:

 

(a)          the
Corporation will be entitled to participate therein at its own expense;

 

(b)          except
as otherwise provided below, the Corporation may, at its option and jointly with any other indemnifying party similarly notified
and electing to assume such defense, assume the defense thereof, with counsel reasonably satisfactory to Agent. After notice from
the Corporation to Agent of its election to assume the defense thereof, the Corporation will not be liable to Agent under this
Agreement for any legal or other expenses subsequently incurred by Agent in connection with the defense thereof except for reasonable
costs of investigation or otherwise as provided below. Agent shall have the right to employ separate counsel in such action, suit
or proceeding but the fees and expenses of such counsel incurred after notice from the Corporation of its assumption of the defense
thereof shall be at the expense of Agent unless (i) the employment of counsel by Agent has been authorized by the Corporation,
(ii) Agent shall have reasonably concluded, and so notified the Corporation, that there is an actual conflict of interest between
the Corporation and Agent in the conduct of the defense of such action, or (iii) the Corporation shall not in fact have employed
counsel to assume the defense of Agent in connection with such action, in any of such cases the fees and expenses of Agent's separate
counsel shall be at the expense of the Corporation. The Corporation shall not be entitled to assume the defense of any action,
suit or proceeding brought by or on behalf of the Corporation or as to which Agent shall have made the conclusion provided for
in clause (ii) above; and

 

(c)          the
Corporation shall not be liable to indemnify Agent under this Agreement for any amounts paid in settlement of any action or claim
effected without its written consent, which shall not be unreasonably withheld or delayed. The Corporation shall be permitted
to settle any action or claim except that it shall not settle any action or claim in any manner which would impose any penalty
or limitation on Agent without Agent's written consent, which may be given or withheld in Agent's sole discretion.

 

8.            Expenses.
The Corporation shall advance, prior to the final disposition of any proceeding, promptly following request therefor, all expenses
incurred by Agent in connection with such proceeding upon the Corporation's receipt of an undertaking by or on behalf of Agent
to repay said amounts if it shall be determined ultimately that Agent is not entitled to be indemnified under the provisions of
this Agreement, the Charter, the Bylaws, the DGCL or otherwise. Such undertaking shall be accepted by the Corporation without
regard to the financial ability of Agent to make such repayment. Without limiting the foregoing, if any action, suit or proceeding
is disposed of on the merits or otherwise (including a disposition without prejudice), without (i) the final disposition being
adverse to Agent, (ii) a final adjudication that Agent was liable to the Corporation, (iii) a plea of guilty (iv) a final adjudication
that Agent did not act in good faith, and in a manner he reasonably believed to be in or not opposed to the best interests of
the Corporation, or (v) with respect to any criminal proceeding, a final adjudication that Agent had reasonable cause to believe
his conduct was unlawful, Agent shall be considered for the purposes hereof to have been wholly successful with respect thereto.

 

    	4

    	 

    

 

9.            Information
Sharing. To the extent that the Corporation receives a request or requests from a governmental third party or other licensing
or regulating organization (the "Requesting Agency"), whether formal or informal, to produce documentation or
other information concerning an investigation, whether formal or informal, being conducted by the Requesting Agency, and such
investigation is reasonably likely to include review of any actions or failures to act by Agent, the Corporation shall promptly
give notice to Agent of said request or requests and any subsequent request. In addition, the Corporation shall provide Agent
with a copy of any and all information or documentation that the Corporation shall provide to the Requesting Agency.

 

10.           No
Imputation. The knowledge and/or actions, or failure to act, of any director, officer, agent or employee of the Corporation
or the Corporation itself shall not be imputed to Agent for purposes of determining any rights under this Agreement.

 

11.           Enforcement.
Any right to indemnification or advances granted by this Agreement to Agent shall be enforceable by or on behalf of Agent in any
court of competent jurisdiction if (i) the claim for indemnification or advances is denied, in whole or in part, or (ii) no disposition
of such claim is made within ninety (90) days of request therefor. Agent, in such enforcement action, if successful in whole or
in part, shall be entitled to be paid also the expense of prosecuting his claim. It shall be a defense to any action for which
a claim for indemnification is made under Section 3 hereof (other than an action brought to enforce a claim for advance or reimbursement
of expenses under this Agreement, provided that the required undertaking has been tendered to the Corporation) that Agent is not
entitled to indemnification because of the limitations set forth in Section 4 hereof. Neither the failure of the Corporation (including
its board of directors or its stockholders) to have made a determination prior to the commencement of such enforcement action
that indemnification of Agent is proper in the circumstances, nor an actual determination by the Corporation (including its board
of directors or its stockholders) that such indemnification is improper shall be a defense to the action or create a presumption
that Agent is not entitled to indemnification under this Agreement or otherwise.

 

12.           Subrogation.
In the event of payment under this Agreement, the Corporation shall be subrogated to the extent of such payment to all of the
rights of recovery of Agent, who shall execute all documents required and shall do all acts that may be necessary to secure such
rights and to enable the Corporation effectively to bring suit to enforce such rights.

 

13.           Non-Exclusivity
of Rights. The rights conferred on Agent by this Agreement shall not be exclusive of any other right which Agent may have
or hereafter acquire under any statute, provision of the Charter or Bylaws, agreement, vote of stockholders or directors, or otherwise,
both as to action in his official capacity and as to action in another capacity while holding office.

 

    	5

    	 

    

 

14.          Survival
of Rights.

 

(a)          The
rights conferred on Agent by this Agreement shall continue after Agent has ceased to be a director, officer, employee or other
agent of the Corporation or to serve at the request of the Corporation as a director, officer, employee or other agent of another
corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, and shall inure to the benefit of Agent's
heirs, executors and administrators.

 

(b)          The
Corporation shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or
substantially all of the business or assets of the Corporation, expressly to assume and agree to perform this Agreement in the
same manner and to the same extent that the Corporation would be required to perform if no such succession had taken place.

 

15.          Separability.
Each of the provisions of this Agreement is a separate and distinct agreement and independent of the others, so that if any provision
hereof shall be held to be invalid or unenforceable for any reason, such invalidity or unenforceability shall not affect the validity
or enforceability of the other provisions hereof. Furthermore, if this Agreement shall be invalidated in its entirety on any ground,
then the Corporation shall nevertheless indemnify Agent to the fullest extent provided by the Charter, the Bylaws, the DGCL or
any other applicable law. 

 

16.          Governing
Law. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware,
without regard to its principles of conflicts of laws. The Corporation and Agent hereby irrevocably and unconditionally (i) agree
that any action or proceeding arising out of or in connection with this Agreement may be brought in the Delaware Court of Chancery,
(ii) consent to submit to the jurisdiction of the Delaware Court of Chancery for purposes of any action or proceeding arising
out of or in connection with this Agreement, (iii) waive any objection to the laying of venue of any such action or proceeding
in the Delaware Court of Chancery, and (iv) waive, and agree not to plead or to make, any claim that any such action or proceeding
brought in the Delaware Court of Chancery has been brought in an improper or inconvenient forum.

 

17.          Amendment
and Termination. No amendment, modification, termination or cancellation of this Agreement shall be effective unless in writing
signed by both parties hereto.

 

18.          Identical
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to
be an original but all of which together shall constitute but one and the same Agreement. Only one such counterpart need be produced
to evidence the existence of this Agreement.

 

19.          Notices.
All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed to have been duly given
(i) upon delivery if delivered by hand to the party to whom such communication was directed or (ii) upon the third business day
after the date on which such communication was mailed if mailed by certified or registered mail with postage prepaid:

 

    	6

    	 

    

  

(a)          If
to Agent, at the address indicated on the signature page hereof.

 

(b)          If
to the Corporation, to:

 

Vringo, Inc.

780 Third Avenue, 15th Floor

New York, NY 10017

Attention: Chief Executive Officer

 

or to such other address
as may have been furnished to Agent by the Corporation.

 

20.         Headings.
The headings of the sections of this Agreement are inserted for convenience only and shall not be deemed to constitute part of
this Agreement or to affect the construction hereof.

 

[Remainder of page intentionally left
blank.]

 

    	7

    	 

    

 

 

[Signature
Page to Indemnification Agreement]

 

IN WITNESS WHEREOF, the parties
hereto have executed this Indemnification Agreement on and as of the day and year first above written.

 

	 	VRINGO, INC.
	 	 	 
	 	 	 
	 	By:	          
	 	Name:  Alexander R. Berger
	 	Title:  Chief Operating Officer
	 	 	 
	 	AGENT
	 	 
	 	 
	 	Address:
	 	780 Third Avenue, 15th Floor, NY NY 10017
	 	 

 

    	8CONFIDENTIAL TREATMENT REQUESTED. Confidential portions of
this document have been

redacted and have been separately filed with the Commission.

 

Exhibit 10.37

 

SUBLICENSE AGREEMENT

 

By And
Between

 

TG
BIOLOGICS, INC.

 

And

 

ILDONG PHARMACEUTICAL CO. LTD.

 

November 13, 2012

 

CONFIDENTIAL

 

    	 

    	 

    

 

TABLE OF CONTENTS

 

	 	 	Page
	 	 	 
	1.	DEFINITIONS	2
	 	 	 
	2.	LICENSE GRANTS; EXCLUSIVITY	17
	 	 	 	 
	 	2.1	Sublicense.	17
	 	2.2	Right to Sublicense.	20
	 	2.3	No Other Rights.	20
	 	2.4	Exclusivity.	20
	 	 	 
	3.	DEVELOPMENT OF PRODUCTS	22
	 	 	 	 
	 	3.1	Development Program.	22
	 	3.2	Development Diligence.	23
	 	3.3	Preparation of Development Plan.	23
	 	3.4	Compliance.	23
	 	3.5	Supply of Compound(s) or Products(s) for Development.	24
	 	3.6	Use of Proprietary Materials.	24
	 	 	 
	4.	REGULATORY ACTIVITIES	24
	 	 	 	 
	 	4.1	Responsibility for Regulatory Filings.	24
	 	4.2	Disclosure; Right of Access.	25
	 	4.3	Disclosure of Certain Events.	25
	 	4.4	Communication with Regulatory Authorities in the SUBLICENSOR Commercialization Territory.	26
	 	 	 
	5.	COMMERCIALIZATION OF PRODUCTS	26
	 	 	 	 
	 	5.1	Commercialization Plan.	26
	 	5.2	Responsibility for Commercialization of Products.	26
	 	5.3	Commercialization Diligence.	27
	 	5.4	Failure to Satisfy Commercialization Diligence Obligations.	27
	 	5.5	Failure to achieve Sales Targets	28
	 	5.6	Compliance.	29
	 	5.7	No Unauthorized Sales.	29
	 	5.8	Records; Reports.	29
	 	5.9	Supply of Product for Commercialization.	30
	 	5.10	Product Recalls.	30
	 	 	 
	6.	SUPPLY OF THE COMPOUND AND/OR PRODUCT	30
	 	 	 	 
	 	6.1	Supply of LFB-R603 for Development and Commercialization.	30
	 	6.2	Supply of TG20 for Development and Commercialization.	31
	 	 	 
	7.	PAYMENTS	31
	 	 	 	 
	 	7.1	Upfront Payment.	31
	 	7.2	Sales Milestones.	31
	 	7.3	Payment of Royalties; Royalty Rates; Accounting and Records.	32

 

    	i

    	 

    

 

	8.	TREATMENT OF CONFIDENTIAL INFORMATION; PUBLICITY	35
	 	 	 	 
	 	8.1	Confidentiality.	35
	 	8.2	Publicity.	36
	 	8.3	No Use of Name.	37
	 	 	 
	9.	INTELLECTUAL PROPERTY RIGHTS	37
	 	 	 	 
	 	9.1	SUBLICENSOR Intellectual Property Rights.	37
	 	9.2	Improvement	37
	 	9.3	Joint Improvement	37
	 	9.4	Patent Coordinators.	38
	 	9.5	Notice; Inventorship.	38
	 	 	 
	10.	FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS	39
	 	 	 	 
	 	10.1	Patent Filing, Prosecution and Maintenance.	39
	 	10.2	Enforcement and Defense.	40
	 	10.3	Trademark Prosecution and Registration.	43
	 	 	 
	11.	TERM AND TERMINATION	44
	 	 	 	 
	 	11.1	Term.	44
	 	11.2	Termination.	44
	 	11.3	Consequences of Termination of Agreement.	45
	 	11.4	Surviving Provisions.	47
	 	 	 
	12.	REPRESENTATIONS AND WARRANTIES	48
	 	 	 	 
	 	12.1	Mutual Representations and Warranties.	48
	 	12.2	Additional Representations of SUBLICENSOR.	48
	 	12.3	Additional Representations of ILDONG.	49
	 	 	 
	13.	INDEMNIFICATION; INSURANCE	50
	 	 	 	 
	 	13.1	Indemnification of SUBLICENSOR by ILDONG.	50
	 	13.2	Indemnification of ILDONG by SUBLICENSOR.	50
	 	13.3	Conditions to Indemnification.	51
	 	13.4	Insurance.	51
	 	13.5	Warranty Disclaimer.	51
	 	13.6	No Warranty of Success.	52
	 	13.7	Limited Liability.	52
	 	 	 
	14.	MISCELLANEOUS	52
	 	 	 	 
	 	14.1	Disputes; Consent to Jurisdiction.	52
	 	14.2	Notices.	52
	 	14.3	Governing Law.	53
	 	14.4	Competition Law.	53
	 	14.5	Binding Effect.	54
	 	14.6	Headings.	54
	 	14.7	Counterparts.	54
	 	14.8	Amendment; Waiver.	54

 

    	ii

    	 

    

 

	 	14.9	No Third Party Beneficiaries.	54
	 	14.10	Purposes and Scope.	54
	 	14.11	Assignment and Successors.	55
	 	14.12	Force Majeure.	55
	 	14.13	Interpretation.	55
	 	14.14	Integration; Severability.	55
	 	14.15	Further Assurances.	56

 

List of Exhibits and Schedules

 

	Exhibit A	Commercial Supply Agreement(s)
	 	 
	Schedule 2	Commercialization Plan
	Schedule 3	Description of LFB-R603
	Schedule 4	Licensed Patent Rights and Background Patent Rights
	Schedule 5	Description of TG20
	Schedule 6	Press Release
	Schedule 7	Licensed Trademarks

 

    	iii

    	 

    

 

SUBLICENSE AGREEMENT

 

This SUBLICENSE AGREEMENT
(this “Agreement”) is entered into as of November 13, 2012 (the “Effective Date”) by and
between TG Biologics, Inc., a Delaware corporation with a principal place of business at 787 Seventh Avenue, 48th Floor,
New York, New York 10019 (“TG” or SUBLICENSOR”) and Ildong Pharmaceutical Co. Ltd., a Korean limited
company with a principal place of business at 60 Yangjae-dong, Seocho-ku, Seoul 137-733 KOREA (“ILDONG”). Each
of ILDONG and SUBLICENSOR is sometimes referred to individually herein as a “Party” and collectively as the
“Parties.”

 

RECITALS

 

WHEREAS, SUBLICENSOR
is clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative and medically
important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs;

 

WHEREAS, ILDONG is
a pharmaceutical company engaged in producing pharmaceutical specialties, pharmaceutical raw materials and environmental products;

 

WHEREAS, prior to the
signature of the present Agreement, SUBLICENSOR has entered into an exclusive license agreement (the “LFB/GTC License”)
with LFB Biotechnologies SAS, LFB/GTC LLC, and GTC Biotherapeutics Inc dated on 30th of January, 2012. (collectively the “Senior
Licensors”) related to the Compounds (as such term is defined below);

 

WHEREAS, pursuant to
the terms of the LFB/GTC License, SUBLICENSOR has acquired rights to certain license agreements related to the Compounds, including:

 

		-	A license agreement with Dr. Hadam on an anti CD 20 monoclonal
antibody, CAT 13.6.E12 and the hybridoma cell-line producing such murine antibody

		-	A license agreement with Pharming on the casein promoter

		-	A license agreement with Start/Viagen on the cloning
and nuclear transfer technology;

 

WHEREAS, pursuant to
Article 2.2 of the LFB/GTC License, SUBLICENSOR retains full rights to grant sublicense to certain patents, technology and material
related to the Compounds;

 

Whereas,
pursuant to that executed term sheet between SUBLICENSOR and ILDONG, dated June 13, 2012, the Parties have agreed to enter into
a license on the terms and subject to the conditions set forth in this Agreement; and

 

Whereas,
in furtherance of such transaction, SUBLICENSOR and ILDONG have also agreed to enter into a Commercial Supply Agreement on the
terms described herein;

 

    	1

    	 

    

 

 NOW, THEREFORE,
in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the Parties hereto,
intending to be legally bound, hereby agree as follows:

 

1.      DEFINITIONS

 

Whenever used in this
Agreement with an initial capital letter, the terms defined in this Article 1 shall have the meanings specified.

 

1.1      “Acceptance”
means, with respect to a Drug Approval Application filed for a Product, the acceptance of such filing by the applicable Regulatory
Authority in any country within the Territory.

 

1.2      “Adverse
Event” means any untoward medical occurrence in a human clinical trial subject or in a patient who is administered a
Compound or Product, whether or not considered related to the compound or product, including any undesirable sign (including abnormal
laboratory findings of clinical concern), symptom or disease associated with the use of a Compound or Product, as defined more
fully in 21 CFR §312.32.

 

1.3      “Affiliate”
means, with respect to any Person, any other Person that, directly or indirectly, controls, or is controlled by, or is under common
control with, such Person. For purposes of this definition, “control” means (a) ownership of more than fifty percent
(50%) of the shares of stock entitled to vote for the election of directors in the case of a corporation, or more than fifty percent
(50%) of the equity interests in the case of any other type of legal entity, (or such lesser maximum percentage permitted in those
jurisdictions where majority ownership by foreign entities is prohibited); (b) status as a general partner in any partnership;
or (c) any other arrangement whereby a Person controls or has the right to control the board of directors of a corporation or equivalent
governing body of an entity other than a corporation.

 

1.4      “Agreement”
means this sublicense agreement and its Exhibits and Schedules listed in the table of contents.

 

1.5      
“Annual Net Sales” means, with respect to any Calendar Year, the aggregate amount of Net Sales for such Calendar
Year.

 

1.6      “Anticipated
Date of Receipt of Marketing Authorization” means, the date of receipt of Marketing Authorization from the applicable
regulatory agency set forth in the Development Plan (Schedule 1)

 

1.7      “API”
means the active pharmaceutical ingredient that is intended to be used in the Manufacture of any Product.

 

    	2

    	 

    

 

 

1.8      “Applicable
Laws” means any national, international, federal, state or local laws, treaties, statutes, ordinances, rules and regulations,
including any rules, regulations, guidance or guidelines of Regulatory Authorities having the binding effect of law, or of any
national securities exchanges or securities listing organizations or other government authorities other than Regulatory Authorities,
that are in effect from time to time during the Term and applicable to a particular activity hereunder.

 

1.9      “Background
Patent Rights” means any Patent Rights that are Controlled by SUBLICENSOR, other than Licensed Patent Rights, containing
one or more claims that could Cover any Compound or Product (including its Manufacture or its formulation or a method of its delivery
or of its use). For the sake of clarity, the Background Patent Rights existing as of the Effective Date are listed on Schedule
4.

 

1.10    “BLA”
means (a) any Biologic License Application, as defined in the FDCA and regulations promulgated thereunder, or any successor
application or procedure required to market and sell a Product in the Territory; and (b) all supplements and amendments to the
foregoing.

 

1.11    “Branding” means all matters relating to the branding of any Product, including any matters related to the selection
of any trademarks, brand names, product logos, branding colors, trade dress, positioning and key messages to be incorporated into
Promotional Materials used for any Product in the Territory.

 

1.12    “Business
Day” means any day other than a Saturday or Sunday on which banking institutions in New York, New York, USA or Seoul,
Korea are open for business.

 

1.13    “Calendar
Quarter” means the period beginning on the Effective Date and ending on the last day of the calendar quarter in which
the Effective Date falls, and thereafter each successive period of three (3) consecutive calendar months ending on March 31, June
30, September 30 or December 31; provided, that, the final Calendar Quarter shall end on the last day of the Term.

 

1.14    “Calendar
Year” means the period beginning on the Effective Date and ending on December 31 of the calendar year in which the Effective
Date falls, and thereafter each successive period of twelve (12) months commencing on January 1 and ending on December 31; provided,
that, the final Calendar Year shall end on the last day of the Term.

 

1.15    “Challenge”
means any challenge to the validity or enforceability of any of the Licensed Patent Rights before any administrative, judicial
or other governmental authority, court, tribunal or arbitration panel, including by (a) filing a declaratory judgment action in
which any of the Licensed Patent Rights is alleged to be invalid or unenforceable; (b) citing prior art pursuant to 35 U.S.C. §301,
filing a request for re-examination of any of the Licensed Patent Rights pursuant to 35 U.S.C. §302 and/or §311, or provoking
or becoming a party to an interference with an application for any of the Licensed Patent Rights pursuant to 35 U.S.C. §135;
or (c) filing or commencing any re-examination, opposition, cancellation, nullity or similar proceedings against any of the Licensed
Patent Rights in any country.

 

    	3

    	 

    

  

1.16      “Change
of Control” means, with respect to ILDONG, a transaction or series of related transactions (including any merger, consolidation,
share exchange, reorganization or combination) involving ILDONG and any Third Party that results in (a) the holders of outstanding
voting securities of ILDONG immediately prior to such transaction ceasing to represent at least fifty percent (50%) of the combined
outstanding voting power of ILDONG or of the surviving or continuing entity immediately after such transaction or series of transactions;
(b) any Third Party (other than a trustee or other fiduciary holding securities under an employee benefit plan) becoming the beneficial
owner of fifty percent (50%) or more of the combined voting power of the outstanding securities of ILDONG (including as a single
Third Party all persons who in concert or act together as a “group” for purposes of acquiring shares of ILDONG, in
accordance with Section 13(d) of the Securities Act of 1934) (other than an investment transaction by an entity not engaged in
the pharmaceutical or biotechnology business, the purpose of which is to raise capital for ILDONG); or (c) the sale or other disposition
to a Third Party of all or substantially all of ILDONG’s assets or business to which this Agreement relates. 

 

1.17      “Clinical
Data” means any and all data (together with all Clinical Trial reports and the results of analyses thereof) derived or
generated from any Clinical Trial of a Compound or Product or from testing of subjects or the analysis of samples used in any such
Clinical Trial.

 

1.18      “Clinical
Trial” means, collectively, any Phase 1 Clinical Trial, Phase 2 Clinical Trial, Phase 3 Clinical Trial, as applicable.

 

1.19      “Combination
Product” means a single product that includes, in combination with a Product, one or more therapeutically-active ingredients
other than a Product that are sold in a single package or as a unit at a single price either as a fixed dosage form or as separate
dosage forms.

 

1.20      “Commercialization”
or “Commercialize” means any and all activities directed to the offering for sale and sale of a Product after
Marketing Authorization has been obtained with respect to such Product, including, (a) activities directed to marketing, promoting,
detailing, distributing, Manufacturing, importing, selling and offering to sell such Product; (b) interacting with Regulatory Authorities
regarding any of the foregoing; and (c) seeking Pricing Approvals and Reimbursement Approvals for such Product (d) Post Approval
Clinical Trials. When used as a verb, “to Commercialize” and “Commercializing” means to engage
in Commercialization and “Commercialized” has a corresponding meaning.

 

    	4

    	 

    

  

1.21      “Commercialization
Plan” means, with respect to any Product, the written report prepared by ILDONG pursuant to Section 5.1 and submitted
to SUBLICENSOR for its review that (a) describes the Commercialization activities that ILDONG reasonably expects to conduct with
respect to such Product in the Territory, and (b) sets forth (i) a non-binding estimate of projected sales of such Product in the
Territory, and (ii) a summary of all actual sales of such Product in the Territory, as such report may be amended or updated by
ILDONG from time to time. Without limiting the foregoing, each Commercialization Plan shall include, without limitation, (a) demographics
and market dynamics, market strategies, a marketing plan (including advertising, detailing forecasts, Pricing strategies pertaining
to discounts and sales forecasts) for the Territory; (b) specific Commercialization and marketing objectives, projected milestones,
resource allocation requirements and activities to be performed over such period (including all anticipated Clinical Trials) (collectively,
the “Commercialization Targets”); (c) a timeline for such activities, including the estimated launch date(s)
in the Territory; (d) a sales and expense forecast (including at least five (5) years of estimated sales and expenses in terms
of both volume and value) for the Territory; (e) Manufacturing plans and the expected product profile; and (f) the expected Regulatory
Filings to be required and prepared, and the expected timetable for making such Regulatory Filings.

 

1.22      
“Commercially Reasonable Efforts” means, with respect to the activities of ILDONG, and/or its Affiliates,
Sublicensees, Distributors, in the Development or Commercialization, as the case may be, of a particular Compound and/or Product,
the level of efforts and resources typically used and expected from a pharmaceutical company of similar size for the development
or commercialization of products of comparable market potential, taking into account all relevant factors including, as applicable,
the stage of development, observed efficacy and safety of the Product and relative to Competitive Products in the marketplace,
actual or anticipated Regulatory Authority approved labeling, the nature and extent of market exclusivity (including patent coverage,
regulatory exclusivity and competitiveness of alternative products), the cost and likelihood of obtaining Marketing Authorization,
the actual or projected profitability, and the reasonably expected and actual pricing, reimbursement and formulary status. For
purposes of clarity, Commercially Reasonable Efforts shall be determined on a market-by-market and Indication-by-Indication basis
for a particular Compound and/or Product, and it is anticipated that the level of effort may be different for different markets
and may change over time, reflecting changes in the status of the Compound or Product and the market(s) involved.

 

1.23      “Competitive
Entity” means any Third Party that (a) together with its Affiliates and subsidiaries, collectively had worldwide sales
of ethical pharmaceutical products, in the Calendar Year that preceded the Change of Control, of at least One Billion Dollars (USD
$1,000,000,000), and (b) on the date of such Change of Control is actively working on any research program involving the
expenditure of funds or the application of full time equivalents in the aggregate amount of at least $500,000 per Calendar Year
involving a Competitive Program.

 

1.24      “Competitive
Products” means any anti CD 20 monoclonal antibody for use in the Field

 

1.25      “Competitive
Program” means any program that involves the research, development or commercialization of any (a) transgenically-derived
chimeric monoclonal antibody or (b) cell-product anti CD 20 monoclonal antibody for use in the Field.

 

    	5

    	 

    

  

1.26      “Completion”
means, with respect to any Clinical Trial, the date on which all material data reasonably expected to be derived therefrom has
been generated and the final study report with respect thereto has been finalized. 

 

1.27      “Compounds”
means ublituximab, collectively, (i) TG20 and/or (b) LFB-R603.

 

1.28      “Confidential
Information” means with respect to each Party, all information, Technology and Proprietary Materials that is (i) ILDONG
Background Technology, in the case of ILDONG and (ii) Licensed Technology, in the case of SUBLICENSOR, and, that, in any case,
is disclosed or provided by or on behalf of such Party (the “Disclosing Party”) to the other Party (the “Receiving
Party”) or to any of the Receiving Party’s employees, consultants, Affiliates or sublicensees; provided, that,
none of the foregoing shall be Confidential Information if: (A) as of the date of disclosure, it is known to the Receiving Party
or its Affiliates as demonstrated by contemporaneous written documentation maintained in the ordinary course of business, other
than by virtue of a prior confidential disclosure to such Receiving Party; (B) as of the date of disclosure it is in the public
domain, or it subsequently enters the public domain through no fault of the Receiving Party; (C) it is obtained by the Receiving
Party from a Third Party having a lawful right to make such disclosure free from any obligation of confidentiality to the Disclosing
Party; or (D) it is independently developed by or for the Receiving Party without reference to or use of any Confidential Information
of the Disclosing Party as demonstrated by contemporaneous written documentation maintained in the ordinary course of business.
For purposes of clarity, (a) unless excluded from Confidential Information pursuant to the preceding sentence, any scientific,
technical, manufacturing or financial information of a Party that is disclosed through any report (including any audit report)
shall constitute Confidential Information of the Disclosing Party; (b) all Clinical Data produced by ILDONG in connection with
the Development of a Compound or Product and/or in the conduct of Clinical Trials shall be Confidential Information of ILDONG;
and (c) any combination of Confidential Information shall not be considered in the public domain or in the possession of the Receiving
Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the
Receiving Party unless the combination and its principles are in the public domain or in the possession of the Receiving Party.

 

1.29      “Control”
or “Controlled” means (a) with respect to Technology (other than Proprietary Materials) or Patent Rights, the
possession by a Party (or an Affiliate of such Party, as applicable) of the right to grant a license or sublicense to such Technology
or Patent Rights as provided herein without violating the terms of any agreement or arrangement with, infringing the Patent Rights
of, or misappropriating the proprietary or trade secret information of, any Third Party and without violating any Applicable Laws
and (b) with respect to Proprietary Materials, the possession by a Party of the right to supply such Proprietary Materials to the
other Party as provided herein without violating the terms of any agreement or arrangement with any Third Party and without violating
any Applicable Laws. Notwithstanding the foregoing, no Party (or Affiliate of a Party, as applicable) shall be deemed to Control
any Technology, Proprietary Materials or Patent Rights solely by virtue of the license grants set forth in this Agreement.

 

    	6

    	 

    

 

1.30      
“Cover” or “Covered” means, with respect to a Product, that the manufacture, use or sale
of such Product in a particular country by an unlicensed Third Party would infringe a Valid Claim.

 

1.31      “Development”
or “Develop” means, with respect to a Product, (a) all non-clinical and clinical drug development activities
that are undertaken after the Effective Date up to and including the date of obtaining of Marketing Authorization of such Product
to obtain including (i) the conduct of Clinical Trials, toxicology and pharmacology testing, test method development and stability
testing, process development (including the Manufacture of validation and engineering batches), formulation development, delivery
system development, quality assurance and quality control development, analytical method development, human clinical studies and
regulatory affairs activities and statistical analysis and report writing; (ii) the preparation of Clinical Trial design and operations;
(iii) preparing and filing Drug Approval Applications, and (b) all activities related to Manufacturing Development and (c) any
and all other activities that may be necessary or useful to obtain Regulatory Approval, Pricing Approval, or Reimbursement Approval.
When used as a verb, “Developing” means to engage in Development and “Developed” has a corresponding
meaning.

 

1.32      “Development
Plan” means, with respect to the Compound and/or any Product, the non-binding written plan for, and estimated budget
applicable to, the Development activities anticipated to be conducted by ILDONG for the Compound and/or Product, as such written
plan may be amended, modified or updated in accordance with Section 3.1.3. Topics that may be covered in the plan, (a) the Clinical
Trials (including investigator-initiated clinical trials) that are expected to be conducted and the expected timeline for conducting
such Clinical Trials; (b) the expected Drug Approval Applications to be required and prepared, and the expected timetable for making
such Drug Approval Applications;

 

1.33      “Development
Program” means (a) the Development activities to be conducted by ILDONG during the Term with respect to the Compounds
and (b) the Development activities to be conducted by SUBLICENSOR during the Term under the Development Services and Manufacturing
Agreement as set forth in the Development Plan and defined in 3.1.2.

 

1.34      “Distributor”
means any Person that purchases Product from ILDONG or any of ILDONG’s Affiliates or Sublicensees for purposes of resale
of Product to end users in the Territory (including any wholesalers, pharmacists or hospitals).

 

    	7

    	 

    

  

1.35      “Divest”
means, with respect to a Competitive Program, a divestiture of such Competitive Program to a Third Party by sale, license or otherwise;
provided, that, if such divestiture is made by ILDONG by way of one or more licenses or sublicenses, (a) ILDONG and its Affiliates
shall not hold or retain any rights with respect to such Competitive Program other than (i) the right to receive license fees,
milestone payments and royalties on sales of products (or other sources of revenue, including with respect to Manufacturing) with
respect to such Competitive Program, (ii) the right to defend claims of infringement, (iii) the right to assert claims of infringement
against Persons who may infringe its intellectual property rights with respect to products with respect to such Competitive Program
and (iv) the right to otherwise control filings and patent term extensions connected with any licensed or sublicensed Patent Rights,
and (b) ILDONG and its Affiliates are not consulted with respect to, and do not otherwise participate in, any decisions (other
than those described in clauses (ii), (iii) and (iv) above), or otherwise collaborate with any Third Party, with respect to (x)
the commercialization of products with respect to such Competitive Program or (y) the commercial strategy with respect to products
with respect to such Competitive Program.

 

1.36      “Drug
Approval Application” means, with respect to a Product in the Territory, an application for Marketing Authorization for
such Product in the Territory. For purposes of clarity, Drug Approval Application shall include, without limitation (a) a counterpart
of an NDA or BLA (as in the US), sNDA or sBLA (as in the US), or MAA (as in Europe) in any country or region in the Territory;
and (b) and all supplements and amendments to the foregoing.

 

1.37      “Excluded
Application” means (a) any application involving the determination or monitoring of (i) the presence or absence of a
disease; (ii) the stage, progression or severity of a disease or (iii) the effect on a disease of a particular treatment; (b) any
application involving the selection of patients for a particular treatment; and (c) any in vitro applications or uses.

 

1.38      “Executive
Officer” means the Chief Executive Officer of SUBLICENSOR and the Chief Executive Officer of ILDONG.

 

1.39      “FDA”
means the United States Food and Drug Administration or any successor agency or authority thereto.

 

1.40      “FDCA”
means the United States Federal Food, Drug, and Cosmetic Act, as amended.

 

1.41      “Field”
means the treatment, control, mitigation, prevention and/or cure of all human therapeutic Indications. For purpose of clarity,
the definition of “Field” shall not include any Excluded Application.

 

1.42      “First
Commercial Sale” means, with respect to a Product in the Territory, the first sale, transfer or disposition for value
to an end user of such Product in the Territory after Marketing Authorization for such Product has been received in the Territory;
provided, that, a First Commercial Sale shall not include: (a) any sale to an Affiliate, Sublicensee or Distributor (unless
the Affiliate, Sublicensee or Distributor is the last entity in the distribution chain of the Product), (b) any use
of a Product in Clinical Trials, pre-clinical studies or other research or development activities, or (c) the disposal or transfer
of Products for a bona fide charitable purpose, including compassionate use or named patient use.

 

    	8

    	 

    

  

1.43      “Force
Majeure” means any occurrence beyond the reasonable control of a Party that (a) prevents or substantially interferes
with the performance by such Party of any of its obligations hereunder and (b) occurs by reason of any act of God, flood, fire,
explosion, earthquake, strike, lockout, labor dispute, casualty or accident, or war, revolution, civil commotion, act of terrorism,
blockage or embargo, or any injunction, law, order, proclamation, regulation, ordinance, demand or requirement of any government
or of any subdivision, authority or representative of any such government.

 

1.44      “GLP”
means the then-current Good Laboratory Practice Standards promulgated or endorsed by the FDA or, in the case of foreign jurisdictions,
comparable regulatory standards promulgated or endorsed by the applicable Regulatory Authority.

 

1.45      “GMP”
means current Good Manufacturing Practices that apply to the Manufacture of API and/or the clinical or commercial supply of Products,
including, without limitation, the United States regulations set forth under Title 21 of the United States Code of Federal Regulations,
parts 210 and 211, as amended from time-to-time, as well as all applicable guidance published from time-to-time by the FDA or,
in the case of foreign jurisdictions, comparable regulatory standards promoted or endorsed by the applicable Regulatory Authority
and the International Conference on Harmonization Guidelines ICHQ7A Good Manufacturing Practice Guidance for API or the principles
and guidelines of Good Manufacturing Practices for Medicinal Products as defined with EC Directive 2003/94/EC and associated EC
Guide to Good Manufacturing Practice.

 

1.46      “Good
Clinical Practice” or “GCP” means the applicable regulations or guidance relating to the design, conduct,
recording, and reporting of Clinical Trials that involve the participation of human subjects, when generating Clinical Trial data
intended to be submitted to Regulatory Authorities, as set forth in the FDCA and any regulations or guidance documents promulgated
thereunder, including but not limited to the ICH E6 consolidated guidance on Good Clinical Practice.

 

1.47      “Hadam
License Agreement” means that certain License Agreement, dated August 15, 2006, by and between LFB Biotechnologies (“LFB”)
and Dr. Martin Hadam and licensed to SUBLICENSOR pursuant to the LFB/GTC License.

 

1.48      “Hatch-Waxman
Act” means the Drug Price Competition and Patent Term Restoration Act of 1984, as amended.

 

1.49      “IND”
means: (a) an Investigational New Drug Application, as defined in the FDCA and regulations promulgated thereunder, or any counterpart,
successor application, or procedure required to initiate clinical testing of a Product in humans in the Territory; and (b) all
supplements and amendments to the foregoing. 

 

1.50      “Indication”
means each separate and distinct disease, illness and/or condition in humans including without limitation Non-Hodgkin's Lymphoma,
Chronic Lymphocytic Leukemia, Lupus, and Rheumatoid Arthritis, for which Regulatory Approval is being sought.

 

    	9

    	 

    

  

1.51      “Investigator’s
Brochure” means a compilation of preclinical and clinical data with respect to a new investigational drug that is proposed
for filing with a Regulatory Authority and used to provide information to clinical investigators and Regulatory Authorities.

 

1.52      “Joint
Improvement” means any Program Technology that is (a) jointly conceived, developed or reduced to practice by one or more
employees of, or consultants to, ILDONG and/or its Affiliates, Sublicensees, Distributors and one or more employees of, or consultants
to, SUBLICENSOR or (b) conceived , developed, or reduced to practice solely by one or more employees of, or consultants to ILDONG
resulting from the use by ILDONG in any material respect of the Licensed Technology, Licensed Patent Rights, Background Patent
Right or SUBLICENSOR Materials.

 

1.53      “Joint
Patent rights” means any Patent Rights related to Joint Improvements.

 

1.54      “Knowledge”
or “Known” means, with respect to a Party, the actual knowledge of the Executive Officer or of
any executive officer (as defined for purposes of Section 14 of the Securities Exchange Act of 1934, as amended) of such Party.

 

1.55      “LFB-R603”
means the cell-culture produced chimeric monoclonal antibody described on Schedule 3 attached hereto and incorporated herein
by reference.

 

1.56      “Licensed
Patent Rights” means any Patent Rights that are Controlled by SUBLICENSOR during the Term and that (a) contain one or
more claims that Cover any Compound or Product; and (b) are necessary or useful for ILDONG to Develop and/or Commercialize
any Compound or Product in the Field and in the Territory. For purposes of clarity, (a) the Licensed Patent Rights existing as
of the Effective Date are listed on Schedule 4 attached hereto and (b) Schedule 4 shall be updated by SUBLICENSOR
by written notice to ILDONG on an annual basis during the Term to include any additional
patents and patent applications not previously listed; provided, that, the exclusion of a patent or patent application from Schedule
4 shall not be deemed to be a conclusive indication of whether that patent or application is or should be considered a “Licensed
Patent Right” for purposes of this Agreement.

 

1.57      “Licensed
Technology” means any Technology that is Controlled by SUBLICENSOR during the Term and that (a) relates to any Compound
or Product and (b) is necessary or useful for ILDONG to Develop, and/or Commercialize any Compound or Product in the Field and
in the Territory.

 

1.58      “Licensed
Trademark” shall mean the registered trademarks listed in Schedule 7 hereto which are owned or controlled by SUBLICENSOR
and which may be used by ILDONG in connection with the sale and marketing of the product in the Territory.

 

    	10

    	 

    

  

1.59      “SUBLICENSOR
Materials” means any Proprietary Materials that are Controlled by SUBLICENSOR and used by SUBLICENSOR, or provided by
SUBLICENSOR for use, in the Development Program.

 

1.60      “SUBLICENSOR
Improvement” means any Program Technology that is conceived or first reduced to practice by employees of, or consultants
to, SUBLICENSOR alone or jointly with any Third Party, without the use, in any material respect, of any ILDONG Materials or Joint
Improvement.

 

1.61      
“Manufacture” or “Manufacturing” or “Manufactured” means
all activities related to the production of any API or Product, including the manufacture, receipt, inspection, storage and handling
of materials, and the manufacture, processing, purification, packaging, labeling, warehousing, quality control testing (including
in-process release and stability testing), shipping and release of API or Product.

 

1.62      “Manufacturing
Development” means, with respect to any API or Product, all activities related to the optimization of a commercial-grade
Manufacturing process for the Manufacture of such API or Product including, test method development and stability testing, formulation,
validation, productivity, trouble shooting and next generation formulation, process development, Manufacturing scale-up, strain
improvements, development-stage Manufacturing, and quality assurance/quality control development.

 

1.63      “Marketing
Authorization” means, with respect to any Product, the Regulatory Approval required by Applicable Laws to market and
sell such Product for use for any Indication including without limitation Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia,
Lupus, and Rheumatoid Arthritis for humans in the Territory.

 

1.64      “NADA”
means a New Animal Drug Application required by the US Food and Drug Administration for the use of any genetically engineered animal
in which the gene coding for the API is stably integrated in the genome of the animal.

 

1.65      “NDA”
means (a) any New Drug Application, as defined in the FDCA and regulations promulgated thereunder, or any counterpart, successor
application, or procedure required to market and sell a Product in the Territory; and (b) all supplements and amendments to the
foregoing.

 

1.66      “Net
Sales” means the gross amount billed or invoiced by ILDONG or any of its Affiliates, Sublicensees or Distributors (each,
a “Seller”) to Third Parties in the Territory for sales or other dispositions or transfers for value of Products
less (a) allowances for trade, quantity and cash discounts actually allowed and taken; (b) freight, transportation, insurance,
postage charges and customs duties included on a Seller’s bill or invoice or as a separate item; (c) credits, rebates, allowances,
and amounts repaid due to returns, recalls or government regulations, including allowances for uncollectible amounts and/or bad
debts on previously sold Products; (d) retroactive price reductions that are actually allowed or granted; (e) sales taxes, excise
taxes, value-added taxes and other taxes (other than income taxes) levied on the invoiced amount; and (f) duties, tariffs and other
governmental charges. In addition, Net Sales are subject to the following:

 

    	11

    	 

    

 

(i)       Net
Sales shall not include sales or transfers between ILDONG and any of its Affiliates, Sublicensees or Distributors unless such Affiliate,
Sublicensee or Distributor is the end user of the Product.

 

(ii)      If
any Seller effects a sale, disposition or transfer of a Product to a Third Party in a particular country other than on customary
commercial terms or for non-monetary consideration, the Net Sales of such Product to such Third Party shall be deemed to be “the
fair market value” of such Product. For purposes of this subsection (ii), “fair market value” means the value
that would have been derived had such Product been sold as a separate product to another customer in the country concerned on customary
commercial terms.

 

(iii)      For
purposes of this Agreement, “sale” shall mean any transfer or other distribution or disposition, but shall not include
transfers or other distributions or dispositions of Product at no charge for academic research, preclinical, clinical, or regulatory
purposes (including the use of a Product in Clinical Trials) or in connection with patient assistance programs or other charitable
purposes or to physicians or hospitals for promotional purposes (including free samples to a level and in an amount which is customary
in the industry and/or which is reasonably proportional to the market for such Product).

 

(iv)     For
the purposes of determining royalty rates and the royalties payable on Combination Products, Net Sales of Product shall be calculated
by multiplying the Net Sales of the Combination Product by the fraction A/A+B, where A is the average selling price, during the
royalty paying period in question, of the Product sold separately in the country in which the sale of the Combination Product is
made, and B is the average selling price, during the royalty period in question, of the other active ingredients or components
sold separately.  In the event that such average selling price cannot be determined for both Product and all other active
ingredients and components included in the Combination Product, Net Sales for purposes of determining payments under this Agreement
shall be calculated by multiplying the Net Sales of the Combination Product by the fraction C/(C+D) where C is the standard fully-absorbed
cost of the Product portion of the combination, and D is the standard fully-absorbed cost of the other active ingredient or component
included in the Combination Product, as determined by ILDONG using its standard accounting procedures consistently applied. In
the event that the standard fully-absorbed cost of the Product and/or the other active ingredients or components included in such
Combination Product cannot be determined, for the purposes of determining royalties payable hereunder, the Parties shall negotiate
in good faith to determine an appropriate commercial value for all the components in the Combination Product and calculate Net
Sales of such Combination Product accordingly.

 

1.67      “Patent
Rights” means the rights and interests in and to issued patents and pending patent applications (which, for purposes
of this Agreement, include certificates of invention, applications for certificates of invention and priority rights) in any country
or region, including all provisional applications, substitutions, continuations, continuations-in-part, divisions, renewals, all
letters patent granted thereon, and all reissues, re-examinations and extensions thereof, and all foreign counterparts of any of
the foregoing.

 

    	12

    	 

    

  

1.68      “Person”
means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited
liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization,
including a government or political subdivision, department or agency of a government.

 

1.69      “Phase
1 Clinical Trial” means a human clinical trial conducted for a Product in any country that would satisfy the requirements
of 21 CFR 312.21(a), as amended (or its foreign equivalent).

 

1.70      “Phase
2 Clinical Trial” means a human clinical trial conducted for a Product for any Indication that would satisfy the requirements
of 21 CFR 312.21(b), as amended (or its foreign equivalent) and is intended to explore one or more doses, dose response, and duration
of effect, and to generate initial evidence of clinical activity and safety for such Product in the target patient population.

 

1.71      “Phase
3 Clinical Trial” means a pivotal human clinical trial conducted for a Product for any Indication that would satisfy
the requirements of 21 CFR 312.21(c), as amended (or its foreign equivalent) and is intended to confirm with statistical significance
the efficacy and safety of such Product with respect to a particular Indication, and is performed to obtain Marketing Authorization.

 

1.72      
“Pivotal Clinical Trial” means (a) a Phase 3 Clinical Trial or, (b) a Phase 2 Clinical Trial to the extent:
(i) in the United States, the protocol for that Phase 2 Clinical Trial shall have been reviewed by the FDA under its current Special
Protocol Assessment Guidelines (or equivalent guidelines issued in the future), and any comments from the FDA on that protocol
are incorporated in the final protocol for that Phase 2 Clinical Trial or are resolved to the FDA’s satisfaction as evidenced
by further written communications from the FDA; or (ii) a process with a comparable result – acceptance of a Phase 2 Clinical
Trial protocol as “potentially pivotal” – has occurred with the EMA/CHMP in the European Union; or (iii) based
on the results of that Phase 2 Clinical Trial, either the FDA, EMA, or corresponding Regulatory Authority in the Territory has
determined that the Phase 2 Clinical Trial can be considered as a pivotal clinical trial for purposes of obtaining Marketing Authorization.

 

1.73      “Post
Approval Clinical Trials” means any Phase 4 clinical trial and/or any clinical trial undertaken after any Marketing Approval
is granted such as Investigator sponsored study.

 

1.74      “Pricing”
means the determination of Product pricing at all levels, including the Product list price (also referred to as Wholesale Acquisition
Cost) and the net price in which the Product is offered to purchasers and payers (including both private sector and government
entities).

 

    	13

    	 

    

  

1.75      “Pricing
Approval” means, with respect to a Product in the Territory, any pricing and reimbursement approvals, guidance or recommendations
reasonably necessary to market such Product in the Territory. 

 

1.76      
“Product” shall mean any pharmaceutical or medicinal item, substance, formulation or dosage that is comprised
of, or contains, a Compound (whether or not such Compound is the sole active ingredient).

 

1.77      “Product
Improvement” means any Program Technology related to or concerning the Product and/or Licensed Technology, whether or
not patentable, copyrightable or otherwise protectable under any intellectual property rights.

 

1.78      “Program
Technology” means any Technology or Proprietary Material that is conceived and first reduced to practice (actually or
constructively), by ILDONG and/or its Affiliates or jointly by the Parties, or by any Sublicensee or by any Distributors, whether
or not patentable, in the conduct of the Development Program and/or in connection with the Commercialization of Products.

 

1.79      “Proprietary
Materials” means any tangible chemical, biological or physical materials that (a) are furnished
by or on behalf of one Party to the other Party in connection with this Agreement, whether or not specifically designated as proprietary
by such Transferring Party, or (b) that are otherwise conceived or reduced to practice by ILDONG in the conduct of the Development
Program and/or in connection with the Commercialization of Products.

 

1.80      
“Regulatory Approval” means, with respect to the Territory, any approval, product and establishment license,
registration or authorization of any Regulatory Authority required for the Manufacture, use, storage, importation, exportation,
transport or distribution of a Product in the Territory, including any Marketing Authorization.

 

1.81      “Regulatory
Authority” means any national, international, regional, state or local regulatory agency, department, bureau, commission,
council or other governmental entity with authority over the distribution, importation, exportation, Manufacture, production, use,
storage, transport, clinical testing, marketing, Pricing or sale of a Product in the Territory.

 

1.82      “Regulatory
Filings” means, collectively: (a) all INDs, NDAs, BLAs, NADAs, MAAs establishment license applications, Drug Master Files,
and all other similar filings (including, without limitation, counterparts of any of the foregoing in the Territory); (b) all supplements
and amendments to any of the foregoing; (c) all data and other information contained in, and correspondence relating to, any of
the foregoing; and (d) any and all orphan drug applications. 

 

1.83      “Reimbursement
Approval” means, with respect to a Product in the Territory, any pricing reimbursement registration or listing
on formularies and all approval necessary to an optimal introduction of the Product on the market.

 

    	14

    	 

    

  

1.84      “Royalty
Term” means with respect to each Product in each country in the Territory, the period beginning on the date of First
Commercial Sale of such Product in such country and ending on the later of (a) the expiration of the last to expire Valid Claim
of the Licensed Patent Rights or ILDONG Program Patent Rights in such country that Covers the composition of matter, Manufacture,
use or sale of such Product, and (b) fifteen (15) years from the date of the First Commercial Sale of such Product in such country.

 

1.85      “Sales
Target” means that proportion of the total patient market for the Product provided to Sublicensor by ILDONG and expressed
as either a percentage or calculated number of vials of the Product as set forth in Schedule 3.

 

1.86      “Serious
Adverse Event” means any untoward medical occurrence that, at any dose, results in death, is life-threatening,
requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity,
or is a congenital anomaly/birth defect, as more full defined in 21 CFR § 312.32.

 

1.87      “Significant
Development Event” means any of the following material Development events, a summary of which shall be included
in any Development Report: (a) any material interaction and/or written correspondence between ILDONG and any Regulatory Authority
with respect to the Compound or a Product; (b) any material event with respect to any Clinical Trial involving the Compound and/or
a Product, including any such event that is ongoing as of the date of the applicable Development Report, or is reasonably expected
to occur or be initiated within twelve (12) months of the date of the applicable Development Report; and (c) any material result
obtained in the conduct of any Clinical Trial involving the Compound and/or a Product during the period covered by the Development
Report. For purposes of clarity, all information provided to SUBLICENSOR with respect to Significant Development Events, shall
be deemed to be Confidential Information of ILDONG. For purposes of this definition, “material” shall be defined as
any event and/or result which have had or may have a significant impact on the activities and timelines defined in the Development
plan of each Product.

 

1.88      “sBLA”
means a Supplemental Biologic License Application, as defined in the FDCA and applicable regulations promulgated thereunder.

 

1.89      “sNDA”
means a Supplemental New Drug Application, as defined in the FDCA and applicable regulations promulgated thereunder.

 

1.90      “Sublicensee”
means any Third Party to which ILDONG grants a sublicense in accordance with Section 2.2.

 

1.91      “Sublicense
Agreement” means any agreement by and between a Party and a Sublicensee which is entered into in accordance with Section
2.2.

 

1.92      
“Technology” means, collectively, all inventions, discoveries, improvements, trade secrets and proprietary
information and methods, whether or not patentable or patented, including without limitation: (a) methods of Manufacture or use
of, and structural and functional information pertaining to, chemical compounds; (b) compositions of matter, data, formulations,
processes, techniques, know-how and results (including any negative results) and (c) results of clinical trials, pre-clinical trials
and other Development activities.

 

    	15

    	 

    

  

1.93      “Territory”
means South Korea, Taiwan, Singapore, Indonesia, Malaysia, Thailand, Philippines, Vietnam, and Myanmar.

 

1.94      “TG20”
means the transgenic-derived chimeric monoclonal antibody described more fully on Schedule 5 attached hereto and incorporated
herein by reference.

 

1.95      “ILDONG
Materials” means any Proprietary Materials that are Controlled by ILDONG and used by ILDONG, or provided by ILDONG for
use, in the Development Program.

 

1.96      
“Third Party” means (a) with respect to ILDONG, any Person other than ILDONG and its respective Affiliates,
Sublicensees and Distributors and (b) with respect to SUBLICENSOR, any Person other than its Affiliates.

 

1.97      “Valid
Claim” means any claim of (a) an issued unexpired patent that (i) has not been finally cancelled, withdrawn, abandoned
or rejected by any administrative agency or other body of competent jurisdiction, (ii) has not been permanently revoked, held invalid,
or declared unpatentable or unenforceable in a decision of a court or other body of competent jurisdiction that is unappealable
or unappealed within the time allowed for appeal, (iii) has not been rendered unenforceable through terminal disclaimer or otherwise,
and (iv) is not lost through an interference proceeding that is unappealable or unappealed within the time allowed for appeal;
or (b) a claim of a pending Patent application, which claim has not been abandoned or finally disallowed without the possibility
of appeal.

 

Additional Definitions.
In addition, each of the following definitions shall have the respective meanings set forth in the section of this Agreement indicated
below:

 

	Definition	 	Section
	 	 	 
	Action	 	10.2.1(a)(ii)
	Anticipated Approval Notice	 	5.11.1(a)
	Claims	 	13.1
	Commercialization Report	 	5.8
	Competitive Program Transaction	 	2.4.2(a)
	Competitive Program Transaction Notice	 	2.4.2(a)
	Development Report	 	3.4.1
	Diligence Failure Notice	 	5.4
	Disclosing Party	 	1.28
	Dispute	 	14.1
	Effective Date	 	Preamble
	Filing Party	 	10.1.4

 

    	16

    	 

    

 

	Definition	 	Section
	 	 	 
	LFB	 	Preamble
	LFB/GTC	 	Preamble
	SUBLICENSOR	 	Preamble
	SUBLICENSOR Indemnities	 	13.1
	ICH	 	3.4
	Indemnified Party	 	13.3
	Indemnifying Party	 	13.3
	Infringement	 	10.2.1(a)(i)
	Infringement Notice	 	10.2.1(a)(i)
	Losses	 	13.1
	Option	 	Recitals
	Option Agreement	 	Recitals
	Party/Parties	 	Preamble
	Patent Coordinator	 	9.4
	Recall	 	5.10
	Receiving Party	 	1.28
	Recipient Party	 	3.6
	ILDONG	 	Preamble
	ILDONG Diligence Failure Notice	 	5.4
	ILDONG Indemnities	 	13.2
	Term	 	11.1
	Transferring Party	 	3.6

 

2.      LICENSE
GRANTS; EXCLUSIVITY

 

2.1     Sublicense.

 

2.1.1      Grant
of Sublicense to ILDONG. Subject to the terms and conditions of this Agreement, SUBLICENSOR hereby grants to ILDONG,
a royalty-bearing, exclusive within the Territory, license or sublicense (with respect to Licensed Technology and/or Licensed Patent
Rights licensed by Third Parties to SUBLICENSOR), including the right to grant sublicenses as provided in Section 2.2, under the
Licensed Technology and Licensed Patent Rights to Develop the Compounds or Products as part of the Development Program and
to Commercialize, use, have used, supply, sell, offer to sell, import, have imported, market, and otherwise Commercialize Products
in the Field in the Territory.

 

In addition, SUBLICENSOR
hereby grants to ILDONG a non-exclusive, fully paid up license or sublicense, including the right to grant sublicenses as provided
in Section 2.2, under the Background Patent Rights to Develop the Compounds or Products as part of the Development Program and
to Commercialize, use, have used, and supply, sell, offer to sell, import, have imported, market, and otherwise Commercialize Products
in the Field in the Territory.

 

    	17

    	 

    

  

2.1.2      Reversion.
Should ILDONG or its Sublicensee(s) stop the Commercialization of any Product, any and all license granted to ILDONG by SUBLICENSOR
in respect of such Product shall automatically revert back to SUBLICENSOR (including licenses granted according to Sections 2.1.1
and 2.1.4). In such case, ILDONG commits to grant to SUBLICENSOR an exclusive, royalty free license or sublicense (with respect
to Rights licensed by Third Parties to ILDONG), including the right to grant sublicenses, under all Patent Rights Controlled by
ILDONG, Joint Improvement and Joint Patent Right necessary or useful for SUBLICENSOR to Develop such Compounds or Product and/or
use, have used, supply, sell, offer to sell, import, have imported, market, and otherwise Commercialize such Products in the Field
and in the Territory.

 

For the avoidance of doubt, the Commercialization of a Product shall be considered as stopped if, after
all Regulatory Approvals and Reimbursement Approvals have been granted in South Korea when:

 

		-	the aggregate amount spent by ILDONG or its Sublicensee(s) on the Commercialization activities is less than $*
per year for such Product; and

 

		-	or,
a minimum of thirty percent (*%) of Sales Target has not been recorded for over a period of more than *
(*) years;

  

2.1.3      Disclosure
of Technology.  SUBLICENSOR shall provide prompt written notice to ILDONG of all Licensed Patent Rights or Licensed
Technology Controlled by SUBLICENSOR and their respective Affiliates that come under the Control of SUBLICENSOR or their respective
Affiliates after the Effective Date during the Term.

 

2.1.4      Grant
of License to Licensed Trademark. 

 

(a)      Ownership
of Trademarks. ILDONG hereby acknowledges that SUBLICENSOR
has already performed a Trademarks research and has registered the Licensed Trademarks. However,
ILDONG is entitled to use and register any other trademarks, on SUBLICENSOR behalf, and at ILDONG’S own cost, for Development
and Commercialization purposes ILDONG agrees that it will not apply
for the registration of the Licensed Trademark (or any mark confusingly similar thereto) anywhere in the world. 

 

(b)      Grant
of License. Subject to the terms and conditions of this Agreement, SUBLICENSOR hereby grants to ILDONG a royalty
bearing, sublicense to use the Licensed Trademark solely for the purpose
of registering, using, Commercializing, importing, exporting, selling, offering for sale, and having sold the Product in
the Field in the Territory on the terms and subject to the conditions set forth in this Agreement.

 

 

*
Confidential material redacted and filed separately with the Commission.

 

    	18

    	 

    

 

(c)      Covenants
of ILDONG. ILDONG hereby agrees that all use of the Licensed Trademark by ILDONG, and any goodwill associated with the
use of the Licensed Trademark by ILDONG, shall inure to the benefit of SUBLICENSOR. ILDONG hereby agrees that nothing in this Agreement
shall give ILDONG any right, title or interest in the Licensed Trademark other than the right to use the Licensed Trademark in
accordance with this Agreement. ILDONG further agrees that it will not: (i) oppose or assist any Third Party in opposing any application
for registration, re-registration or renewal of the Licensed Trademark; ii) apply for or otherwise seek (or assist any Third Party
in applying for or otherwise seeking) complete or partial revocation, cancellation, invalidation or removal of the Licensed Trademark
from any register or (iii) challenge or bring (or assist any Third Party in challenging or bringing) any proceeding or action in
relation to the use or ownership of the Licensed Trademark.

 

(d)      Registration
of Licensed Trademark. SUBLICENSOR shall have the sole right to apply for registration of the Licensed Trademark in the
Territory to the extent such registration has not already been obtained by SUBLICENSOR at the Effective Date and for paying all
applicable fees, including all registration and application fees and renewal fees. SUBLICENSOR shall update attached the Schedule
7 for ILDONG’s use of the Licensed trademarks in the Territory prior to the NDA in each country..

 

(e)      Use
of Licensed Trademark. ILDONG shall use the Licensed Trademark solely (i) in the manner specified in this Agreement and
(ii) in connection with the Product and not for any other goods or services. ILDONG agrees not to use any other trademark or service
mark in combination with the Licensed Trademark without the prior written consent of SUBLICENSOR. ILDONG, at its sole cost and
expense, will provide to SUBLICENSOR representative samples of all products, product packaging, literature, brochures, signs, and
advertising materials prepared by ILDONG which bear, display, or include any reference to the Licensed Trademark, and ILDONG shall
obtain the written approval of SUBLICENSOR with respect to all such materials prior to the use thereof. ILDONG will not distribute
or otherwise use any samples or materials or other media bearing or displaying the Licensed Trademark unless and until SUBLICENSOR
has notified ILDONG in writing of SUBLICENSOR’s approval, which approval shall not be reasonably withheld.

  

(f)      Notice.
ILDONG shall promptly notify SUBLICENSOR (i) of any claim, threat, lawsuit, filing, or other notice or allegation of infringement
of which it is aware regarding ILDONG’s use of the Licensed Trademark and/or (ii) if it becomes aware of the existence of
any Third Party applications to register anywhere in the world any mark or name which consists of or incorporates the Licensed
Trademark. SUBLICENSOR shall have the sole right, but not the obligation, to bring infringement, unfair competition, or other claims
or proceedings involving the Licensed Trademark and ILDONG hereby acknowledges and agrees that it shall have no such right. If
requested by SUBLICENSOR, ILDONG shall cooperate with SUBLICENSOR in connection with any such action.

 

    	19

    	 

    

  

		2.2	Right to Sublicense.

 

2.2.1      Sublicense.
ILDONG shall have the right to grant sublicenses under the licenses granted to it under Section 2.1.1 to any Sublicensee; with
SUBLICENSOR prior written notification provided, that, (a) the terms of each such sublicense shall be consistent with the rights
and obligations of ILDONG under the Agreement; (b) it shall be a condition of any such sublicense that such Sublicensee agrees
to be bound by the terms of this Agreement applicable to the Development and Commercialization of Products in the Field in the
Territory; (c) ILDONG shall provide SUBLICENSOR with a copy of any such Sublicense Agreement within ten (10) days of the execution
of each such Sublicense Agreement; and (d) ILDONG shall not be relieved of its obligations pursuant to this Agreement as a result
of such sublicense, except to the extent such obligations are satisfactorily performed by any such sublicense.

 

2.2.2      Grant
of Rights to Distributors. ILDONG or any of its Affiliates and Sublicensees shall have the right, with SUBLICENSOR prior
written notification, to appoint one or more Distributors for Products in the Territory. ILDONG shall provide SUBLICENSOR with
a copy of each such agreement with any Distributor within ten (10) days of execution of such agreement.

 

		2.3	No Other Rights.

 

2.3.1      ILDONG
shall have no rights to use or otherwise exploit Licensed Technology, Licensed Patent Rights, or SUBLICENSOR Proprietary Materials,
and SUBLICENSOR shall have no rights to use or otherwise exploit ILDONG Technology, ILDONG Patent Rights or ILDONG Proprietary
Materials, in each case, except as expressly set forth in this Agreement.

 

		2.4	Exclusivity.

 

2.4.1      Exclusivity
Obligation.  During the Term of this Agreement, ILDONG shall not, and shall cause each of its Affiliates to not,
conduct any activity, either on its own, or with, for the benefit of, or sponsored by, any Third Party, that, in any case, involves
the research, development or commercialization of any other anti CD 20 monoclonal antibody, or any compound that embodies or is
derived from any anti CD 20 monoclonal antibody, for use in the Field that is competitive with or adversely affects the Development
or Commercialization of any of the Compounds or Products, except hereunder in connection with the research, Development and/or
the Commercialization of the Compounds and Products. Notwithstanding the foregoing, at ILDONG’s request, SUBLICENSOR may
allow ILDONG to Develop and Commercialize all combinations with the Compounds and Products which would be benefit in improving
the Development and/or the Commercialization of the Compounds and Products, such consent to not be unreasonably withheld.

 

    	20

    	 

    

  

		2.4.2	Competitive Program Transaction.

 

(a)      Notice.
If at any time during the Term, ILDONG grants a sublicense or other rights to any Third Party to utilize any Technology or Patent
Rights Controlled by ILDONG or any of its Affiliates for the Development or Commercialization of any of the Compounds or Products,
or ILDONG undergoes a Change of Control, or if ILDONG or any of its Affiliates acquires all or substantially all of the assets
or common stock of a Third Party (whether by asset or stock purchase, merger, consolidation, share exchange or other similar transaction)
and, in any such case, such Third Party or any of such Third Party’s Affiliates (in the case of a Third Party Sublicensee
or a Third Party acquirer of ILDONG), has a Competitive Program (a “Competitive Program Transaction”), ILDONG
shall provide SUBLICENSOR with prompt written notice describing such Competitive Program Transaction in reasonable detail
which shall include a description of the nature of such Competitive Program
(the “Competitive Program Transaction Notice”). Such Competitive Program Transaction Notice shall be provided
by ILDONG prior to execution of such agreement, if permitted under Applicable Laws and not prohibited by the terms of any agreement
between ILDONG or any of its Affiliates and any Third Party, and otherwise as soon as practicable thereafter and, in any event,
not later than promptly following the consummation of the transaction contemplated by such agreement.

 

(b)      Meeting
of the Parties. As soon as practicable following SUBLICENSOR’S receipt of any Competitive Program Transaction
Notice, the Parties shall meet to discuss whether,
notwithstanding any provision hereof, such
Competitive Program would continue following such Competitive Program Transaction. In any such meeting the Parties will review
any restrictions applicable to such Competitive Program that may prevent its combination with this Agreement, and other issues
that may impact the potential combination of such Competitive Program with this Agreement. 

 

(c)      Integration
of Competitive Program.
If ILDONG and SUBLICENSOR mutually agree that such Competitive Program may be integrated into this Agreement, then within *(*)
days
after such determination the Parties shall agree upon an amendment to this Agreement that will provide either (X) (i) that
each compound or product that is part of the Competitive Program would be deemed to be a Compound,
whether or not such compound or product meets the standards or criteria hereunder for a Compound and (ii) the
Parties’ rights and obligations under this Agreement will apply in all relevant respects to any such deemed Compounds
(including the payment of the milestones, and royalties
set forth in this Agreement) or (Y) that the Development and Commercialization diligence standards of this Agreement shall be
revised to ensure that the effort and resources that the Third Party applies (or ILDONG, if ILDONG is the surviving entity) applied
to the Competitive Program shall be equally applied to the Development and Commercialization of the Compounds and Products. 

 

(d)      Termination/Divesting
of Competitive Program.
If the Parties are unable to reach agreement on the terms pursuant to which the integration of any Competitive Program into this
Agreement would occur, ILDONG shall have an additional * (*) days during which it shall determine whether
to (i) terminate the Competitive Program or (ii) Divest itself of the Competitive Program. If ILDONG notifies SUBLICENSOR in writing
that it will terminate such Competitive Program, ILDONG shall promptly terminate such Competitive Program as quickly as possible
with due regard for patient safety and the rights of any subjects that are participants in any clinical studies relating to such
Competitive Program and Applicable Laws, and in any event within * (*) days after its delivery of such written
notice to SUBLICENSOR. If ILDONG notifies SUBLICENSOR in writing that it will Divest itself of the Competitive Program, then it
shall do so as promptly as practicable but in any event on or before *
(*) months from
the date of such notice; provided, that, during the period during which such Divestiture is pending, ILDONG shall maintaining
separate teams working on such Competitive Program and this Agreement. If ILDONG does not notify SUBLICENSOR in writing at the
conclusion of the * (*) day period provided above that ILDONG will terminate or Divest itself of such Competitive
Program, or if ILDONG does so notify SUBLICENSOR but fails to terminate or Divest the Competitive Program within the periods provided
above, SUBLICENSOR shall have the right to immediately terminate this Agreement by providing written notice to ILDONG.

 

 

*
Confidential material redacted and filed separately with the Commission.

 

    	21

    	 

    

 

3.      DEVELOPMENT
OF PRODUCTS

 

For the sake of clarity, in this Section
3, ILDONG means ILDONG, and where applicable, its Affiliates, Sublicensees, and Distributors.

 

		3.1	Development Program.

 

3.1.1      Objective
of Development Program. The objective of the Development Program shall be the Development by ILDONG, in conjunction with
the Development activities of the SUBLICENSOR, of the Compounds and Products in the Field in order to obtain Marketing Authorization
for such Products in the Field in the Territory as promptly as practicable.

 

3.1.2      Responsibility
for Development. ILDONG shall have the sole right and responsibility for, and shall have full control and authority
over, at its sole cost and expense (including without limitation all costs attributable to the supply of Product for the conduct
of Clinical Trials), the Development of Products in the Territory, including conducting all Development activities (including bridging
study(ies), if such study(ies) are necessary due to regulatory gaps) beyond the Development activities being conducted by the SUBLICENSOR
outside of the Territory (which should be supportive of obtaining Marketing Authorization by the FDA and/or EMA, but may or may
not be sufficient to support the obtaining of Marketing Authorization in the Territory) and establishing the methods and means
by which it performs such activities under this Agreement. Should ILDONG, for any regulatory filing, desire to utilize data from
any clinical trials or studies conducted in indications outside *, *, *, and *, which
have been fully funded by the SUBLICENSOR, ILDONG shall pay to the SUBLICENSOR *% of the full cost of the trial which
produced such data. ILDONG shall have the right to engage Third Party contractors to perform any of its Development activities
in the Territory, provided such Third Party contractors are approved by SUBLICENSOR, such approval not to be unreasonably withheld,
and subject to the execution by each such Third Party contractor of an agreement containing provisions that are consistent with
and comparable in scope to, Articles 7 and 8 of this Agreement.

 

 

*
Confidential material redacted and filed separately with the Commission.

 

    	22

    	 

    

 

3.2      Development
Diligence.

 

ILDONG, and/or its
Affiliates, Sublicensees, and Distributors shall use Commercially Reasonable Efforts during the Term to commit such resources (including
employees, consultants, contractors, facilities, equipment and materials) as may be required to support the obtaining of Market
Authorization in the Territory as further described in 3.1.2.

 

3.3      Preparation
of Development Plan. 

 

A Development Plan
in the Territory shall be prepared by ILDONG for each Product and discussed with the SUBLICENSOR for its information and clinical
development and manufacturing planning purposes no less than annually after the Effective Date. During the period commencing on
and after such date and continuing for the remainder of the Term, each party shall prepare and provide to the other party additional
Development Plans detailing any amendments, modifications and/or updates to any existing Development Plan, within thirty (30) days
of the end of each Calendar Year. ILDONG shall seek health authority scientific advice to determine the pivotal studies deemed
necessary for product registration in the Territory at the earliest possible time. The advice received should be reflected in updated
Development Plans. In the event of any conflict between the terms of the Development Plan and the terms and conditions of this
Agreement, the terms and conditions of this Agreement shall prevail..

 

3.4      Compliance.

 

The Parties shall perform
their activities under the Development Program in good scientific manner and in compliance in all material respects with all Applicable
Laws. For purposes of clarity, with respect to each Development activity performed that will or would reasonably be expected to
be submitted to a Regulatory Authority in support of a Regulatory Filing or Drug Approval Application, ILDONG shall not willfully
fail to comply in all material respects with GLPs, GMPs or Good Clinical Practices (or, if and as appropriate under the circumstances,
International Conference on Harmonization (“ICH”) guidance or other comparable regulation and guidance of any
Regulatory Authority in the Territory).

 

3.4.1      Records;
Reports. ILDONG and/or its Affiliates, Sublicensees, and Distributors shall (a) maintain records of its activities under
the Development Program in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes, which
shall fully and properly reflect all work performed and results achieved in the performance of the Development Program and (b)
ILDONG shall keep SUBLICENSOR regularly informed of the progress of its efforts to Develop Products in the Territory. To facilitate
such progress updates, each Party shall provide the other Party with an annual development report (each, a “Development Report”)
(to be delivered with each annual update to the Development Plan) that summarizes: (a) significant Development activities conducted
during the preceding Calendar Year and results obtained with respect to Compounds and Products (including the status of all Clinical
Trials), (b) Significant Development Events applicable to the Compounds and/or Products, (c) a summary of all Program Technology
conceived or reduced to practice by the Parties over such period, (d) a non-binding estimate of the expected timing of any milestone
events with respect to Products and (e) such other information that each Party has in its possession as may be reasonably requested
from time to time by the other party. The Development Plan and each Development Report shall be deemed Confidential Information.
Following the commencement of Commercialization, Development Reports will no longer be required and will be replaced by the annual
Commercialization Report as described in Section 5.8.

 

    	23

    	 

    

  

3.5      Supply
of Compound(s) or Products(s) for Development.

 

SUBLICENSOR’s
and ILDONG’s rights and responsibilities pertaining to the supply of the Compound or the Product for the Development shall
be governed by Section 6 below.

 

3.6      Use
of Proprietary Materials.

 

From time to time during
the Term, either Party (the “Transferring Party”) may supply the other Party (the “Recipient Party”)
with Proprietary Materials of the Transferring Party for use in the Development Program. In connection therewith, each Recipient
Party hereby agrees that (a) it shall not use such Proprietary Materials for any purpose other than exercising its rights or performing
its obligations hereunder; (b) it shall use such Proprietary Materials only in compliance with all Applicable Laws; (c) it shall
not transfer any such Proprietary Materials to any Third Party without the prior written consent of the Transferring Party, except
for the transfer of Products for use in Clinical Trials or as otherwise expressly permitted hereby; (d) the Recipient Party shall
not acquire any right, title or interest in or to such Proprietary Materials as a result of such supply by the Transferring Party;
and (e) upon the expiration or termination of the Development Program, the Recipient Party shall, if and as instructed by the Transferring
Party, either destroy or return any such Proprietary Materials that are not the subject of the grant of a continuing license hereunder.

 

4.      REGULATORY
ACTIVITIES

 

For the sake of clarity, in this Section
4, ILDONG means ILDONG, and where applicable, its Affiliates, Sublicensees and Distributors.

 

4.1      Responsibility
for Regulatory Filings.

 

Subject
to the remainder of this Article 4, (a) ILDONG shall have the sole right and responsibility, at its sole cost and expense, for
preparing and filing all Regulatory Filings and Drug Approval Applications, Pricing Approval applications, or Reimbursement Approval
applications required to Develop Compounds and Commercialize Products in the Territory in its own name; (b) all Regulatory Approvals
for Products shall be solely owned by ILDONG; and (c) ILDONG shall have the sole right and responsibility for (i) maintaining
all Regulatory Filings and/or Marketing Authorizations and (ii) reporting to any Regulatory Authority within the Territory all
Adverse Events and Serious Adverse Events related to any Product if and to the extent required by Applicable Laws. To maximize
market protection of Product, ILDONG may file for any orphan drug designations as appropriate within requisite timeframes prior
to the submission of any Marketing Authorization Application. Firstly, within *
(*) months following the QA approval of the Study Report of the last Clinical Trial as per the Development Program,
ILDONG shall file, or cause to be filed, before the Regulatory Authority (KFDA) in South Korea, all authorization and registration
applications required for the promotion, marketing, distribution and sale of Product in South Korea. ILDONG shall exercise Commercially
Reasonable Efforts to obtain Marketing Authorizations with respect to the Product. Failure to meet this obligation will be considered
a material breach of the Agreement and SUBLICENSOR shall have the right to terminate the Agreement for breach of ILDONG in accordance
with Section 11.2.2.

 

 

*
Confidential material redacted and filed separately with the Commission.

 

    	24

    	 

    

 

4.2      Disclosure;
Right of Access.

 

Upon request from SUBLICENSOR,
ILDONG shall promptly provide SUBLICENSOR with (a) a list of all sites at which Clinical Trials with respect to Products are being
conducted by or on behalf of ILDONG; (b) copies of all Clinical Trial protocols and Investigator’s Brochures with respect
to such Clinical Trials; and (c) access to all data (including non-clinical and Clinical Data), results and information found in
ILDONG’s regulatory files produced by or on behalf of ILDONG, or any of its Affiliates or Sublicensees, in connection with
the conduct by ILDONG of Development activities in its original format, without translation except that translations shall be provided
at no charge where such translations are produced in the ordinary course of business. SUBLICENSOR shall maintain the confidentiality
of such data, results and information and shall only have the right and license to use such data (including Clinical Data), results
and information provided by ILDONG under this Section 4.2 for the performance of its obligations and exercise of its rights under
this Agreement,

 

4.3      Disclosure
of Certain Events.

 

The Parties hereby
agree to report to each other all Adverse Events and/or Serious Adverse Events with respect to the Product (whether occurring in
any Clinical Trial conducted with regard to the Product or in connection with the commercialization of the Product in any country),
within timeframes consistent with its reporting obligations under Applicable Laws and in any event, if either Party is actively
conducting a clinical trial under its own IND or commercializing the Product under its own Marketing Authorization, then the other
Party shall report such events no later than three (3) business days for Serious Adverse Event, and quarterly for Adverse Events,
which report shall, in each case, include the circumstances and nature of such Serious Adverse Event or Adverse Event as required
for reporting under Applicable Laws. In addition, to the extent requested by either Party, the other Party shall promptly provide
to the requesting Party any other information or materials that the requesting Party may require to provide to any Regulatory Authority
with respect to any such Adverse Event or Serious Adverse Event. All disclosures made under this Section 4.3 shall be deemed Confidential
Information of the disclosing Party; provided, that, the Party receiving such disclosures may, upon written notice to the disclosing
Party, report the occurrence, circumstances and nature of such Adverse Event and/or Serious Adverse Event to any Regulatory Authority
solely insofar as such reporting is required to comply with Applicable Laws.

 

    	25

    	 

    

 

4.4        Communication
with Regulatory Authorities in the SUBLICENSOR Commercialization Territory.

 

4.4.1      Participation
in Meetings. ILDONG shall use reasonable efforts to provide SUBLICENSOR with at least thirty (30) days advance notice of
any official meeting with a Regulatory Authority regarding any Marketing Authorization for any Product in the SUBLICENSOR Commercialization
Territory and SUBLICENSOR may elect to send one (1) person reasonably acceptable to ILDONG to participate as an observer (at SUBLICENSOR’S
sole cost and expense) in such meeting.

 

4.4.2      Access;
Notice of Meetings.  ILDONG shall use reasonable efforts to provide SUBLICENSOR with at least thirty (30) days’ advance
notice of any official meeting with Regulatory Authority in the SUBLICENSOR Commercialization Territory regarding any Drug Approval
Application for Products and/or any such audit or inspection conducted by any Regulatory Authority at any site at which Clinical
Trials with respect to Products are being conducted and SUBLICENSOR may elect to send representatives reasonably acceptable to
ILDONG to participate as an observer in such meeting at SUBLICENSOR’ sole cost and expense.

 

5.      COMMERCIALIZATION
OF PRODUCTS

 

For the sake of clarity, in this Section
5, ILDONG means ILDONG, and where applicable, its Affiliates, Sublicensees and Distributors.

 

5.1        Commercialization
Plan. 

 

The initial Commercialization
Plan in the territory shall be prepared by ILDONG and submitted to SUBLICENSOR for its review as soon as practicable after the
submission of the NDA application in South Korea. On and after such date and continuing for the remainder of the Term, additional
Commercialization Plans and/or amendments, modifications and/or updates to the Commercialization Plan, shall be prepared by ILDONG
and submitted to SUBLICENSOR for its review within thirty (30) days of the end of each Calendar Year.

 

5.2        Responsibility
for Commercialization of Products. 

 

Subject to Section
5.11 below, ILDONG shall have the primary right and responsibility for, and shall have primary control and authority over, at its
sole cost and expense, (a) all aspects of the Commercialization of Products in the Field in the Territory including the sole responsibility
for booking sales of Product and for all returns, charge-backs and rebates with respect to Products; and (b) the conduct of all
pre-marketing, marketing, Branding, promotion, sales, distribution, import and export activities (including securing pricing, reimbursement,
sales and marketing and conducting any post-marketing trials or post-marketing safety surveillance and maintaining databases) applicable
to the Commercialization of Products in the Field and in the Territory.

 

    	26

    	 

    

 

5.3      Commercialization
Diligence.  

 

ILDONG
shall use Commercially Reasonable Efforts during the Term to Commercialize Products for all approved Indications in the Field
and in the Territory. Without limiting the foregoing, (a) commencing no later than *
(*) days prior to the estimated date of First Commercial Sale of the Product, ILDONG shall conduct pre-marketing activities
in the Territory with respect to the Product and (b) following receipt of Marketing Authorization with respect to the Product
in the Territory, ILDONG shall initiate and conduct such promotional activities determined by ILDONG as may be required to develop
a commercial market for, launch and Commercialize the Product (including through direct conduct with key opinion leaders) in the
Territory. In addition, ILDONG, shall establish and maintain a well-trained sales force for the Product, (together with a well-trained
support staff) adequate to service all the customers of ILDONG and to keep the sales force knowledgeable and fully informed as
to the Product; maintain an effective distribution system for the Product in the Territory; transport and store the Product to
preserve its quality in accordance with pre-determined QA requirements; obtain and maintain all licenses, approvals and permits
in the Territory necessary for ILDONG to perform its obligations under this Agreement; establish and maintain suitable systems
and records to enable a recall of Product in a timely, efficient and accurate manner and otherwise in accordance with applicable
laws and regulations in the Territory; abide by all applicable rules and regulations relating to sales, marketing and reimbursement;
ensure that no Product shipped by ILDONG is adulterated or misbranded; maintain adequate control over the physical security of
the Product; Cause all Affiliates, sublicensees and subcontractors of ILDONG to comply with the above.

 

5.4      Failure
to Satisfy Commercialization Diligence Obligations. 

 

SUBLICENSOR shall have
the right, in its sole discretion, to provide ILDONG with written notice if it reasonably believes ILDONG has failed to satisfy
its Commercialization diligence obligations under this Agreement (a “ILDONG Diligence Failure”). Such written
notice (a “Diligence Failure Notice”) shall set forth in reasonable detail the nature of the alleged failure
and shall request written justification, in the form of detailed reasons that would support the proposition that ILDONG has satisfied
such diligence obligations. ILDONG shall provide such written justification to SUBLICENSOR within thirty (30) days after receipt
of such Diligence Failure Notice and shall identify any Commercially Reasonable Justifications (as defined below) applicable thereto.
If ILDONG fails to provide SUBLICENSOR with a Commercially Reasonable Justification within such thirty (30) day period ILDONG
shall have an additional (90) day period to cure such failure. During that period a penalty equal to the * shall
accrue on a monthly basis, to the benefit of SUBLICENSOR. Should ILDONG’s failure continue within this additional period,
ILDONG shall continue to pay the penalty abovementioned and SUBLICENSOR reserves the right in
its discretion to, in addition to all damages caused in relation thereof, convert the licenses
and rights granted under any or all of Section 2.1 from exclusive licenses to non-exclusive licenses only as such licenses and
rights apply to such Product. Should ILDONG’s failure continue within an additional hundred eighty (180) day period, ILDONG
shall continue to pay the penalty abovementioned and SUBLICENSOR reserves the right in its discretion to, in addition to
any other remedies it may have as a result of all damages caused in relation thereof, terminate
any or all of the licenses and rights granted under Section 2.1 hereof with respect to the Product that is the subject of the Diligence
Failure Notice termination or conversion, as the case may be, shall be at the discretion of SUBLICENSOR and be effective immediately
upon issuance by SUBLICENSOR of written notice to ILDONG specifying the remedy that SUBLICENSOR is electing to exercise under this
Section 5.4.

 

 

*
Confidential material redacted and filed separately with the Commission.

 

    	27

    	 

    

 

For purposes of this Section 5.4, “Commercially
Reasonable Justification” means the existence or occurrence of one or more of the following events or justifications:
(i) the occurrence of an event of Force Majeure; (ii) the adoption by a Regulatory Authority of any one or more regulations that
become effective after the Effective Date and that materially affect the Development or clinical testing of the Product or the
process for obtaining any Regulatory Approval, Pricing Approval, or Reimbursement Approval for the Product; and (iii) the occurrence
of any event, condition or circumstance (including an event, condition or circumstance related to the manufacture or supply of
the Product (or any material component thereof) for clinical studies or a regulatory action by any Regulatory Authority) with respect
to the Product (or any material component thereof) that (A) involves the safety, toxicity, efficacy or pharmacokinetics of the
Product or (B) prevents the use of the Product in humans (including, without limitation, as a result of patent or other blocking
rights) and, in the case of clauses (A) or (B) above, is not attributable to (1) a breach by ILDONG of any obligation under this
Agreement, (2) the failure of ILDONG to comply with any protocol, development plan or Applicable Laws with respect to the development
of the Product, or (3) any grossly negligent or willful act or omission of ILDONG; or (C) that the ILDONG Diligence Failure is
caused by ILDONG’s failure to take actions that would be in excess of Commercially Reasonable Efforts; provided, that, in
any such case, ILDONG shall use Commercially Reasonable Efforts to mitigate the effect and duration of any such acceptable delay
with respect to the Product that is the subject of the Diligence Failure Notice.

 

5.5        Failure
to achieve Sales Targets

 

5.5.1      Initial
Period. For the * following the date of First
Commercial Sale (the "Initial Period") ILDONG shall achieve the Sales Target. If ILDONG fails to achieve *
percent (*%) of the Sales Target by completion of the Initial Period, ILDONG shall, within * (*)
*, pay to SUBLICENSORS a sum equal to the *. For purposes of this Agreement, “Commercial Years”
means the period commencing on the date of First Commercial Sale of a Product and ending on the anniversary thereof and thereafter
each successive period of twelve (12) months.

 

5.5.2      Subsequent
Periods. For Commercial Years subsequent to the Initial Period ILDONG shall achieve the Sales Target. If ILDONG
fails to achieve * percent (*%) of the Sales Target for any Commercial Year subject to the Initial Period,
ILDONG shall, within * pay to SUBLICENSOR a sum equal to the *.

 

 

*
Confidential material redacted and filed separately with the Commission.

 

    	28

    	 

    

 

In addition to the
above, if ILDONG fails to achieve * percent (*%) of the Sales Target for *, SUBLICENSOR shall
have the right to terminate this Agreement with respect to each country within the Territory where * were not achieved.
In the case where SUBLICENSOR exercises its rights to terminate this Agreement, SUBLICENSOR shall provide * (*)
months prior notice of termination and purchase back any Product stock held by ILDONG valued at the commercial price. If during
the above mentioned * month period, ILDONG achieves * for such six-month period, then ILDONG shall be deemed
to have cured the breach and the termination shall be null and void.

 

5.6      Compliance.

 

ILDONG shall use its
Commercially Reasonable Efforts to Commercialize the Products in compliance in all material respects with all Applicable Laws.

 

5.7      
No Unauthorized Sales.

 

ILDONG shall not, and
shall not permit its Affiliates and not permit Sublicensees or Distributors to, distribute, market, promote, offer for sale or
sell the Product to any Third Party in any country in the Territory that ILDONG, or its Affiliates, Sublicensees or Distributors,
as applicable, reasonably believes is reasonably likely to engage in an unauthorized distribution, marketing, promotion, or sale
of the Product outside the country of purchase.

 

5.8      Records;
Reports.

 

ILDONG shall (a) maintain
records of its Commercialization activities under this Article 5 in sufficient detail, which shall fully and properly reflect all
work done and results achieved in the Commercialization of Products and (b) following the commencement of Commercialization of
the Products provide SUBLICENSOR with annual written reports (each, a “Commercialization Report”) which shall
(i) summarize ILDONG’s efforts to Commercialize Products, (ii) identify the Regulatory Filings and Drug Approval Applications
with respect to such Product that ILDONG or any of its Affiliates or Sublicensees have filed, sought or obtained in the prior twelve
(12) month period or reasonably expect to make, seek or attempt to obtain in the following twelve (12) month period and (iii) summarize
all Clinical Data generated by ILDONG with respect to Products. Commencing no later than ninety (90) days from the date of receipt
by ILDONG of the first Marketing Authorization for each Product and on each anniversary thereof until the expiration of the Royalty
Term applicable to such Product, each such Commercialization Report shall also include (i) an outline of the key sales and marketing
activities that ILDONG reasonably expects to conduct with respect to Product in the Territory, (ii) a non-binding estimate of projected
sales of Product in the Territory for the subsequent three (3) Calendar Year period and (iii) such additional information that
it has in its possession as may be reasonably requested by SUBLICENSOR regarding the Commercialization of any Product, which request
shall not be made more than once each Calendar Year. The Commercialization Plan and Commercialization Report can be provided as
one document.

 

 

*
Confidential material redacted and filed separately with the Commission.

 

    	29

    	 

    

 

5.9      Supply
of Product for Commercialization. 

 

SUBLICENSOR’s
and ILDONG’s rights and responsibilities pertaining the supply of the Compound for the Commercialization shall be governed
by Section 6 below.

 

5.10      Product
Recalls.

 

In the event that any
Regulatory Authority issues or requests a recall or takes similar action in connection with a Product in the Territory, or in the
event ILDONG reasonably believes that an event, incident or circumstance has occurred that may result in the need for a recall,
market withdrawal or other corrective action regarding a Product in the Territory (each, a “Recall”), ILDONG
shall promptly advise SUBLICENSOR thereof by e-mail, telephone or facsimile. Following such notification, ILDONG shall have the
sole right to decide, and have control of, whether to conduct a recall or market withdrawal (except in the event of a recall or
market withdrawal mandated by a Regulatory Authority, in which case it shall be required) or to take other corrective action in
the Territory and the manner in which any such recall, market withdrawal or corrective action shall be conducted; provided, that,
ILDONG shall keep SUBLICENSOR reasonably informed regarding any such Recall. All expenses incurred by ILDONG in connection with
any such Recall (including, without limitation, expenses for notification, destruction and return of the affected Product and any
refund to customers of amounts paid for such Product) shall be the sole responsibility of ILDONG.

 

6.      SUPPLY
OF THE COMPOUND AND/OR PRODUCT 

 

6.1      Supply
of LFB-R603 for Development and Commercialization.

 

SUBLICENSOR shall use
its Commercially Reasonable Effort to provide supply of LFB-R603 as required for the Development and Commercialization of LFB-R603
when and as required by ILDONG for the Development of Products in the Territory. All supplies of Compound and Product for Clinical
Trials supplied by SUBLICENSOR shall be billed to ILDONG at a cost equal to *.

 

For sake of clarity, SUBLICENSOR and its affiliates shall have
the exclusive right and responsibility to provide supply of LFB-R603 as required for Development and Commercialization in the Territory.

 

 

*
Confidential material redacted and filed separately with the Commission.

 

    	30

    	 

    

 

6.2      Supply
of TG20 for Development and Commercialization.

 

Provided that TG20 has
satisfactorily completed non-clinical development, as defined by the acceptance of an IND by the US FDA, SUBLICENSOR shall use
its Commercially Reasonable Effort to provide supply of TG20 as required for the Development and Commercialization of TG20 when
and as required by ILDONG for the Development and Commercialization of Products in the Territory. All supplies of Compound and
Product for Clinical Trials supplied by SUBLICENSOR shall be billed to ILDONG at a cost equal to *.

 

For sake of clarity,
SUBLICENSOR and its affiliates shall have the exclusive right and responsibility to provide supply of TG20 as required for Development
and Commercialization in the Territory. Nothing in this section shall be construed as an obligation on the part of SUBLICENSOR
to continue the development of TG20.

 

Upon
the approval of the first Drug Approval Application by ILDONG within any country within the Territory and the subsequent determination
of the National Health Insurance (“NHI”) price, the parties will enter into a Commercial Supply Agreement which shall
be attached in Exhibit B as soon as it is executed by the Parties and which shall include such customary terms of such agreements
and shall include the payment by ILDONG to SUBLICENSOR at a transfer price not to exceed *%
of the NHI price obtained by the relevant health authority including margin for Cost of Goods manufactured, such that such supply
price is not below *. In the event that commercial supply price to ILDONG exceeds *% of the NHI price, the
Parties agree to renegotiate the Sales Royalty Rates outlined in Section 7.3 in good faith. For the sake of clarity, in no way
shall SUBLICENSOR provide commercial supply to ILDONG at a price that is below *. 

 

7.      PAYMENTS

 

7.1      Upfront
Payment. 

 

In consideration for
the rights granted to ILDONG hereunder, ILDONG hereby agrees to pay to SUBLICENSOR a non-refundable, non-creditable license fee
of two million dollars (USD $2,000,000) within thirty (30) calendar days after the Effective Date.

 

7.2      Sales
Milestones.

 

7.2.1      Sales
Milestones. ILDONG shall make the following non-refundable, non-creditable milestone payments to SUBLICENSOR upon
the occurrence of each of the following milestone events for the first Product that achieves the corresponding Net Sales milestone
for the first time in the combined territory of South Korea and Taiwan:

 

 

*
Confidential material redacted and filed separately with the Commission.

 

    	31

    	 

    

 

	 	 	 	Milestone 	 
	Milestone Event	 	 	Payment	 
		 	 	 	 
	1.      On achieving annual Net Sales of USD $*	 	 	$*	 
	 	 	 	 	 
	2.      On achieving annual Net Sales of USD $*	 	 	$*	 
	 	 	 	 	 
	3.      On achieving annual Net Sales of USD $*	 	 	$*	 
	 	 	 	 	 
	4.      On achieving annual Net Sales of USD $*	 	 	$*	 

 

7.2.2       Notice
and Payment of Milestones.

 

(a)          Notice
of Milestone Events. ILDONG shall provide SUBLICENSOR with prompt written notice upon the occurrence of each milestone
event set forth in Section 7.2.1. In the event that, notwithstanding the fact that ILDONG has not given such a notice, SUBLICENSOR
believes any such milestone event has occurred, it shall so notify ILDONG in writing and shall provide to ILDONG data, documentation
or other information that supports its belief.  Any dispute under this Section 7.2.2(a) that relates to whether or not a milestone
event has occurred shall be resolved in accordance with Section 14.1.

 

(b)          Single
Milestone Payments. ILDONG shall make a milestone payment corresponding to each of the foregoing milestone events only
once under Section 7.2.1, regardless of (i) the number of Products that achieve such milestone event and (ii) the number of times
such milestone event occurs with respect to a Product. For the sake of clarity, each milestone event shall only trigger one milestone
payment.

 

7.3          Payment
of Royalties; Royalty Rates; Accounting and Records.

 

7.3.1       Payment
of Royalties.  Subject to the remainder of this Section 7.3, ILDONG shall pay SUBLICENSOR a non-refundable,
non-creditable royalty on Annual Net Sales of the Product. The rate of such royalty being determined by the amount of Annual Net
Sales as described below:

 

	Annual Net Sales	 	Royalty Rate
	 	 	 
	Up to $* USD	 	*%
	 	 	 
	Between $* and $* USD	 	*%
	 	 	 
	Between $* and $* USD	 	*%
	 	 	 
	Exceeding $* USD	 	*%

 

 

* Confidential
material redacted and filed separately with the Commission.

 

    	32

    	 

    

 

The royalty rate shall
be applied to Annual Net Sales of each Product in each Calendar Year (or partial Calendar Year) commencing with the First Commercial
Sale of such Product in any country in the Territory and ending upon the last day of the last Royalty Term for such Product in
such country. For purposes of clarity, Annual Net Sales shall be determined separately for each separate Product that is sold in
a given Calendar Year.

 

7.3.2       Adjustments
to Royalties for Generic Products. In the event that a Third Party sells a Generic Product (as defined below) in a country
in which a Product is then being sold and such Generic Product is not covered by a Valid Claim under the Licensed Patent Rights
or ILDONG Program Patent Rights in such country, then during the period in which sales of the Generic Product by such Third Party
are equal to at least *
percent (*%) of ILDONG’s volume-based market share of the Product in such country (as measured by
prescriptions or other similar information available in such country), the royalty rate applicable to Net Sales of the Product
in such country shall be reduced to * percent (*%).  Notwithstanding the foregoing, ILDONG’s right
to reduce its royalty obligation under this Section 7.3.3(1) shall expire on the first day of the Calendar Quarter immediately
following the Calendar Quarter in which sales of such Generic Product account for less than * percent (*%)
of ILDONG’s volume-based market share of the Product in such country (as measured by prescriptions or other similar information
available in such country). For purposes of this Section 7.3.3), a “Generic Product” means a biosimilar product with
the same amino acid sequence as the Compound.

 

7.3.3       Payment
Dates and Reports. Royalty Payments. Royalty payments shall be made by ILDONG with respect to each Product within
thirty (30) calendar days after the end of each Calendar Quarter in which sales of such Product occur, commencing with the Calendar
Quarter in which the First Commercial Sale of such Product occurs. ILDONG shall also provide, at the same time each such payment
is made, a report showing: (a) the Net Sales of each Product by type of Product and country in the Territory and, if applicable,
by Combination Product; (b) the total amount of deductions from gross sales to determine Net Sales; (c) the applicable royalty
rate for Product in each country in the Territory after applying any reductions set forth above; and (d) a calculation of the amount
of royalty due to SUBLICENSOR.

 

 

* Confidential
material redacted and filed separately with the Commission.

 

    	33

    	 

    

 

7.3.4       Records;
Audit Rights. ILDONG and its Affiliates, Sublicensees and Distributors shall keep and maintain for three (3) years
from the date of each payment of royalties hereunder complete and accurate records of gross sales and Net Sales by ILDONG and
its Affiliates, Sublicensees and Distributors of each Product, in sufficient detail to allow royalties to be accurately determined.
SUBLICENSOR shall have the right for a period of three (3) years after receiving any such royalty payment to appoint at its expense
an independent certified public accountant reasonably acceptable to ILDONG to audit the relevant records of ILDONG and
its Affiliates, Sublicensees and Distributors to verify that the amount of each such payment was correctly determined; provided,
that, (a) if requested by ILDONG, SUBLICENSOR shall cause the independent certified public accountant to enter into a confidentiality
agreement reasonably acceptable to ILDONG and (b) such independent certified public accountant may only disclose to SUBLICENSOR
whether the royalties paid are correct and the details with respect to any discrepancies. ILDONG and its Affiliates, Sublicensees
and Distributors shall each make its records available for audit by such independent certified public accountant during regular
business hours at such place or places where such records are customarily kept, upon thirty (30) days written notice from SUBLICENSOR.
Such audit right shall not be exercised by SUBLICENSOR more than once in any Calendar Year or more than once with respect to sales
of a particular Product in a particular period. All records made available for audit shall be deemed to be Confidential Information
of ILDONG. The results of each audit, if any, shall be binding on both Parties absent manifest error. In the event there was an
underpayment of royalties by ILDONG hereunder, ILDONG shall promptly (but in any event no later than thirty (30)
days after ILDONG’s receipt of the report so concluding) make payment to SUBLICENSOR of any shortfall. SUBLICENSOR shall
bear the full cost of such audit unless such audit discloses an underpayment by ILDONG of *
percent (*%) or more of the aggregate amount of royalties payable in any Calendar Year, in which case ILDONG
shall reimburse SUBLICENSOR for all costs incurred by SUBLICENSOR in connection with such audit.

 

7.3.5       Overdue
Payments. All royalty payments not made within the time period set forth in Section 7.3.5, and all milestone payments not
made within the time period specified in Section 7.2.1, shall bear interest at the rate of * percent (*%)
per month until paid in full or, if less, the maximum interest rate permitted by Applicable Laws. Any such overdue royalty
or milestone payment shall, when made, be accompanied by, and credited first to, all interest so accrued.

 

7.3.6       Payments;
Withholding Tax; Currency Restrictions.

 

(a)          Payments
in United States Dollars. Except as set forth in Section 6.3.7(b) below, all payments made by ILDONG under this Article
6 shall be made by wire transfer in United States Dollars in accordance with wire transfer instructions provided to ILDONG in writing
from time to time by SUBLICENSOR. If in any Calendar Quarter, Net Sales are made in any currency other than United States Dollars,
such Net Sales shall be converted into United States Dollars as follows:

 

(A/B), where

 

A = foreign “Net Sales”
(as defined above) in such Calendar Quarter expressed in such foreign currency; and

 

B = foreign exchange conversion
rate, expressed in local currency of the foreign country per United States Dollar (using, as the applicable foreign exchange rate,
the spot purchase rate published in the Financial Times on the last Business Day of each Calendar Quarter in which any payment
is due and payable or any other mutually agreed upon source, for such Calendar Quarter).

 

 

* Confidential
material redacted and filed separately with the Commission.

 

    	34

    	 

    

 

(b)          Tax
Withholding. If Applicable Laws require withholding of income or other taxes imposed upon any payments made by ILDONG to SUBLICENSOR
under this Agreement, ILDONG shall (i) make such withholding payments as may be required, (ii) subtract such withholding payments
from such payments to be made to SUBLICENSOR, (iii) submit appropriate proof of payment of the withholding taxes to SUBLICENSOR
within a reasonable period of time, and (iv) promptly provide SUBLICENSOR with all official receipts with respect thereto.

 

(c)          Currency
Restrictions. If any restrictions on the transfer of currency exist in any country in which Products are sold that prevent
ILDONG from making royalty payments thereon in United States Dollars, ILDONG shall make royalty payments on the sales in such country
in the local currency by deposit in a local bank or other depository designated in writing by SUBLICENSOR (or, in the absence of
such designation, at a local bank or other depository selected by ILDONG and identified by ILDONG by written notice to SUBLICENSOR).

 

8.          TREATMENT
OF CONFIDENTIAL INFORMATION; PUBLICITY

 

8.1           Confidentiality.

 

8.1.1       Confidentiality
Obligations. SUBLICENSOR and ILDONG each recognize that the other Party’s Confidential Information and Proprietary
Materials constitute highly valuable assets of such other Party. SUBLICENSOR and ILDONG each agrees that, (a) subject to Section
8.1.2, during the Term and for an additional ten (10) years after termination or expiration of this Agreement it will not disclose,
and will cause its Affiliates, Sublicensees (with respect to ILDONG) and Distributors or Sublicensees (with respect to SUBLICENSOR)
not to disclose whether directly or indirectly, in any manner whatsoever, any Confidential Information or Proprietary Materials
of the other Party and (b) it will not use, and will cause its Affiliates, Sublicensees (with respect to ILDONG) and Distributors
or Sublicensees (with respect to SUBLICENSOR) not to use, any Confidential Information or Proprietary Materials of the other Party,
without the prior written consent of the Disclosing Party, except as expressly permitted hereunder.

 

8.1.2       Limited
Disclosure. SUBLICENSOR and ILDONG each agrees that disclosure of its Confidential Information or any transfer of its Proprietary
Materials may be made by the other Party on a need-to-know basis to any employee, consultant or Affiliate of such other Party or,
to the extent the other Party is ILDONG, to any Third Party subcontractor engaged by ILDONG pursuant to Section 2.2, in each case
solely to the extent reasonably necessary to enable such other Party to exercise its rights or to carry out its responsibilities
under this Agreement; provided, that, any such disclosure or transfer shall only be made to Persons who are bound by written obligations
comparable in scope to the obligations described in Section 8.1.3. SUBLICENSOR and ILDONG each further agrees that the other Party
may disclose its Confidential Information (a) on a need-to-know basis to such other Party’s legal and financial advisors,
(b) as reasonably necessary in connection with an actual or potential (i) permitted sublicense of such Party’s rights hereunder,
(ii) debt or equity financing of such other Party or (iii) acquisition, consolidation, share exchange or other similar transaction
involving such Party and any Third Party, (c) to the extent the other Party is ILDONG, to any Third Party that is or may be engaged
by ILDONG to perform services in connection with the Commercialization of Products as necessary to enable such Third Party to perform
such services, (d) as reasonably necessary to make Regulatory Filings with respect to Products under this Agreement or to respond
to any inquiry made by any Regulatory Authority with respect to Products and to prosecute or maintain Patent Rights, or to file,
prosecute or defend litigation related to Patent Rights, in accordance with this Agreement; (e) as required by Applicable Laws
(which shall be determined by the Disclosing Party in its reasonable discretion); provided, that, in the case of any disclosure
under this clause (e), the Disclosing Party shall (i) if practicable, provide the other Party with reasonable advance notice of
and an opportunity to comment on any such required disclosure and (ii) if requested by the other Party, cooperate in all reasonable
respects with the other Party’s efforts to obtain confidential treatment or a protective order with respect to any such disclosure,
at the other Party’s expense.

 

    	35

    	 

    

 

 

8.1.3       Employees
and Consultants. SUBLICENSOR and ILDONG each hereby covenants and agrees that all of its employees and consultants, and
all of the employees and consultants of its Affiliates, who have access to Confidential Information or Proprietary Materials of
the other Party will, prior to having such access, be bound by written obligations to maintain such Confidential Information or
Proprietary Materials in confidence that are no less stringent than those confidentiality and non-use provisions contained in this
Agreement. Each Party agrees to use, and to cause its Affiliates to use, reasonable efforts to enforce such obligations and to
prohibit its employees and consultants from using such information except as expressly permitted hereunder. Each Party will be
liable to the other Party for any disclosure or misuse by its employees of Confidential Information or Proprietary Materials of
the other Party.

 

		8.2	Publicity.

 

Notwithstanding anything
to the contrary in Section 8.1, the Parties, upon the execution of this Agreement, shall jointly issue a press release with
respect to this Agreement to be reasonably agreed by the Parties in substantially the form attached hereto as Schedule 6,
and either Party may make subsequent public disclosure of the contents of such press release without further approval of the other
Party. Subject to the foregoing, except as required by Applicable Laws (including those relating to disclosure of material information
to investors), neither Party shall issue a press or news release or make any similar public announcement (it being understood that
publication in scientific journals, presentation at scientific conferences and meetings and the like are intended to be covered
by Section 8.4 and not subject to this Section 8.2) related to the terms or existence of this Agreement or the conduct of the Development
Program or the Commercialization of Products without the prior written consent of the other Party; provided, however, that either
Party may make such a disclosure (a) to the extent required by Applicable Laws (including the requirements of any nationally recognized
securities exchange, quotation system or over-the-counter market on which such Party has its securities listed or traded), or (b)
to any investors, prospective investors, lenders and other potential financing sources who are obligated to keep such information
confidential. In the event that such disclosure is required as aforesaid, the disclosing Party shall make reasonable efforts to
provide the other Party with notice beforehand and to coordinate with the other Party with respect to the wording and timing of
any such disclosure. Once any press release or any other written statement is approved for disclosure by both Parties, either Party
may make subsequent public disclosure of the contents of such statement without the further approval of the other Party.

 

    	36

    	 

    

 

8.3           No
Use of Name.

 

Neither Party shall
use the name of the other Party in any Promotional Materials or advertising without the prior express written permission
of the other Party.

 

9.          INTELLECTUAL
PROPERTY RIGHTS

 

For sake of clarity, in this Section 9,
SUBLICENSOR means SUBLICENSOR and, where applicable, Senior Licensors pursuant to the terms of the LFB/GTC License, certain responsibilities
of which may be delegated to Senior Licensors, but for the sake of this Agreement will be overseen by SUBLICENSOR.

 

9.1           SUBLICENSOR
Intellectual Property Rights.

 

SUBLICENSOR shall have
ownership of all right, title and interest, or license to, on a worldwide basis in and to any and all Licensed Technology and Licensed
Patent Rights.

 

9.2           Improvement

 

		9.2.1	ILDONG agrees to notify SUBLICENSOR of each Product Improvement
ILDONG, its Affiliates, or its Sublicensees has developed, conceived or acquired during the Term of this Agreement. ILDONG shall,
upon request of SUBLICENSOR, provide to SUBLICENSOR all data and specifications concerning such Product Improvement. All Product
Improvements shall be deemed to be considered as a “Joint Improvement”.

 

		9.2.2	All SUBLICENSOR Improvement shall be the exclusive and
sole property of SUBLICENSOR and shall become Background Patent Right or Licensed Patent Rights, as the case may be.

 

9.3           Joint
Improvement

 

		9.3.1	Subject to any other provision to the contrary that may
be contained in SUBLICENSOR’s Licenses as defined in Section 2.1.1, any Joint Improvement shall be jointly owned by ILDONG
and SUBLICENSOR.

 

    	37

    	 

    

 

		9.3.2	ILDONG shall have the exclusive, fully paid-up, irrevocable,
transferable right to Use such Joint Improvements in order to Develop the Compounds or Products as part of the Development Program
and to Commercialize, use, have used, Manufacture, have Manufactured, supply, sell, offer to sell, import, have imported, market,
and otherwise Commercialize Products in the Field, within the Territory with the right to sublicense.

 

		9.3.3	Each Party has the exclusive, fully paid-up, irrevocable,
transferable right to Use such Joint Improvements in order to develop and to commercialize have used, Manufacture, have Manufactured,
supply, sell, offer to sell, import, have imported, market, any product other than the Product and Compound.

 

		9.3.4	Each Party shall reasonably assist the other in preparing,
prosecuting and maintaining Patent Rights for Joint Improvements pursuant to section 9.4; 9.5 and 10.

 

9.4           Patent
Coordinators.

 

Each Party shall, by
written notice to the other Party, appoint a patent coordinator reasonably acceptable to the other Party (each, a “Patent
Coordinator”) to serve as such Party’s primary liaison with the other Party on matters relating to the filing, prosecution,
maintenance and enforcement of Patent Rights. Each Party may replace its Patent Coordinator at any time by notice in writing to
the other Party. The initial Patent Coordinators shall be:

 

For SUBLICENSOR:Hari
Miskin

 

For ILDONG:

 

		9.5	Notice; Inventorship.

 

 

The Parties hereby
agree to promptly notify to the other Party, through the Patent Coordinators, of the conception or reduction to practice of any
Program Technology or Joint-Improvement and to promptly execute any documents that may be necessary to perfect SUBLICENSOR’s
rights in and to such Program Technology or Joint-Improvement. The Patent Coordinators shall determine inventorship of Program
Technology or Joint-Improvement under U.S. patent law. In case of a dispute between the Patent Coordinators over inventorship and,
as a result, whether any particular Technology is SUBLICENSOR Technology or Joint Improvement, such dispute shall be resolved according
to U.S. patent law by patent counsel selected by the Patent Coordinators who (and whose firm) is not at the time of the dispute,
and was not at any time during the five (5) years prior to such dispute, performing services for either of the Parties. Expenses
of such patent counsel shall be shared equally by the Parties.

 

    	38

    	 

    

 

10.         FILING,
PROSECUTION AND MAINTENANCE OF PATENT RIGHTS

 

10.1         Patent
Filing, Prosecution and Maintenance. 

 

10.1.1           SUBLICENSOR
Prosecution Rights.  SUBLICENSOR shall have the sole right and responsibility to prepare and file applications with
respect to, and prosecute and maintain, at its sole discretion, and using patent counsel or agents of its choice, all Licensed
Patent Rights (including all Joint Patent Rights that are Licensed Patent Rights) throughout the Territory. ILDONG shall cooperate
with and assist SUBLICENSOR in all reasonable respects, in connection with SUBLICENSOR’s preparation, filing, prosecution
and maintenance of Licensed Patent Rights.

 

10.1.2           ILDONG
Prosecution Rights. ILDONG shall have the sole right and responsibility to prepare and file applications with respect to,
and prosecute and maintain, at its sole cost, expense and discretion, and using patent counsel or agents of its choice, all ILDONG
Program Patent Rights throughout the Territory. SUBLICENSOR shall cooperate with and assist ILDONG in all reasonable respects,
in connection with ILDONG’s preparation, filing, prosecution and maintenance of ILDONG Program Patent Rights.

 

10.1.3           Joint
Patent Rights.  Subject to Section 10.1.1, within ten (10) Business Days after it is determined pursuant to Section 9.5
that any particular Program Technology is Joint Improvement, the Parties will determine which Party will undertake the prosecution
of such Joint Patent Rights based on the respective expertise of the Parties and the rights of the Parties under this Agreement.
If the Parties fail to agree within such ten (10) Business Day period, then prosecution of such Patent Rights shall be jointly
controlled by the Parties, using patent counsel agreed upon by the Patent Coordinators. All patent costs and expenses incurred
by a Party or jointly by the Parties in connection with the preparation, filing, prosecution and maintenance of Joint Patent Rights
in the Territory that cover any Product for use in the Field shall be shared equally by the Parties. Provided however that, if
a Party refuses, declines or fails to assume its obligations under this section 11.1.2, it shall advise the other Party and said
other Party shall have the right, at its own expense, to prepare, prosecute and maintain Patent Rights for Joint Improvements.
In such a case, upon request of the non-defaulting Party, the Party that refuses, declines or fails to file, prosecute or maintain
any such Patent Rights for Joint Improvements shall assign all its co-ownership rights to the other Party.

 

10.1.4           Information
and Cooperation. The Parties hereby agree to cooperate with each other in connection with the filing, prosecution and maintenance
of Patent Rights under this Agreement, including through the prompt execution and delivery of documents and instruments as may
reasonably be required in connection therewith. Without limiting the foregoing, each Party responsible for the filing, prosecution
and/or maintenance of Patent Rights under Sections 10.1.1 and/or 10.1.2 above (a “Filing Party”) shall (a) promptly
provide the other Party with copies of all patent applications filed hereunder and other material submissions and correspondence
with applicable patent offices, in sufficient time to allow for review and comment by the other Party; (b) provide the other Party
and its patent counsel with an opportunity to consult with the Party and its patent counsel regarding the filing and contents of
any such application, amendment, submission or response; and (c) take into consideration in good faith the advice and suggestions
of the other Party and its patent counsel in connection with such filing.

 

    	39

    	 

    

  

10.1.5       Interference,
Opposition, Reexamination and Reissue.

 

(a)          Notice.
Not more than thirty (30) days following the discovery by either Party of any request for, or the filing or declaration of, any
interference, opposition, or reexamination proceeding with respect to any Licensed Patent Rights in the Territory, the discovering
or determining Party shall notify the other Party of such event.

 

(b)          Primary
Responsibility and Cooperation. SUBLICENSOR shall have primary responsibility, at its own expense, with respect to the course
of action taken to defend or prosecute any such interference, opposition, reexamination or reissue, except that the Parties shall
share equally the reasonable fees and expenses incurred under this Section 10.1.4(b) with respect to Joint Patent Rights. The Parties
shall cooperate fully with each other and each shall provide to the other any information or assistance that the other may reasonably
request with respect to any course of action taken under this Section 10.1.4. SUBLICENSOR shall (a) keep ILDONG reasonably informed
of all developments in such interference, opposition, reexamination or reissue in the Territory, including to the extent permissible,
the status of any settlement negotiations and the terms of any offer related thereto and (b) provide to ILDONG copies of all submissions
or agreements arising in connection with such proceeding sufficiently in advance of their filing or due date so as to give ILDONG
sufficient time to comment thereon, and SUBLICENSOR shall give good faith consideration to ILDONG’s comments, with due regard
to the other Party’s rights and commercial interests under this Agreement. Neither Party shall enter into any settlement
or consent decree regarding Joint Patent Rights, or assent to the grant of any reissued or reexamined patent within the Joint Patent
Rights, without the prior written consent of the other Party, which shall not be unreasonably withheld or delayed.

 

10.1.6       Decision
Not to File; Abandonment. SUBLICENSOR shall notify ILDONG in the event SUBLICENSOR decides at any time to abandon or discontinue
prosecution of any one or more of the patents or patent applications included in the Licensed Patent Rights and in the Territory.
Such notification will be given as early as possible which in no event will be less than fifteen (15) days prior to the date on
which said patent(s) or patent application(s) will become abandoned. ILDONG shall have the option, exercisable upon written notification
to SUBLICENSOR, to assume full responsibility, at its discretion for the prosecution of the affected patent(s) or patent application(s),
which shall be conducted in the name of ILDONG. 

 

10.2     Enforcement
and Defense.

 

10.2.1       Third
Party Infringement.

 

(a)          In
General.

 

(i)          Notice.
In the event either Party becomes aware of (i) any suspected infringement or misappropriation of any Licensed Patent Rights, Joint
Patent Rights that covers the development or commercialization of a Compound or Product in the Field in the Territory, or (ii)
the submission by any Third Party of an abbreviated NDA under the Hatch-Waxman Act for a product in the Field that comprises the
Compound (each, an “Infringement”), that Party shall promptly notify the other Party and provide it with all
details of such Infringement of which it is aware (each, an “Infringement Notice”). The Patent Coordinators
shall promptly meet to discuss the Infringement and the strategy for patent enforcement with respect to such Infringement.

 

    	40

    	 

    

 

 

(ii)         SUBLICENSOR
Right to Enforce.  SUBLICENSOR shall have the first right, but not the obligation, to address any such Infringement
in the Territory by taking reasonable steps, which may include the institution of legal proceedings or other actions (each, an
“Action”), and to compromise or settle such Action; provided, that, (A) SUBLICENSOR shall keep ILDONG reasonably
informed about such Action, (B) ILDONG shall provide reasonable cooperation to SUBLICENSOR in connection with such Action, (C)
SUBLICENSOR shall not take any position with respect to, or compromise or settle, such Action in any way that would be reasonably
likely to directly and adversely affect the scope, validity or enforceability of the Licensed Patent Rights without the prior consent
of ILDONG, which consent shall not be unreasonably withheld, and (D) if SUBLICENSOR does not intend to prosecute or defend an Infringement,
or determines to cease to pursue such an Action, it shall promptly inform ILDONG and Section 10.2.1(a)(iii) shall apply. SUBLICENSOR
shall incur no liability to ILDONG as a consequence of such Action or any unfavorable decision resulting therefrom, including
any decision holding any such claim invalid, not infringed or unenforceable.  All costs, including, without limitation,
attorneys’ fees, relating to such legal proceedings or other action shall be borne by SUBLICENSOR.

 

(iii)        ILDONG
Right to Enforce. If (A) SUBLICENSOR informs ILDONG that SUBLICENSOR does not intend to prosecute an Action in respect of any
Licensed Patent Rights or Joint Patent Rights pursuant to Section 10.2.1(a)(ii), (B) within sixty (60) days after the Infringement
Notice, SUBLICENSOR has not commenced any Action, or (C) if SUBLICENSOR determine to cease to pursue any such Action with respect
to such Infringement, then ILDONG shall have the right, at its own expense, upon notice to SUBLICENSOR to take appropriate action
to address such Infringement, including by initiating its own Action or taking over prosecution of any Action initiated by SUBLICENSOR;
provided, that, in such event, (1) ILDONG shall keep SUBLICENSOR reasonably informed about such Action and shall consult with SUBLICENSOR
before taking any major steps during the conduct of such Action, (2) SUBLICENSOR shall provide reasonable cooperation to ILDONG
in connection with such Action, and (3) ILDONG shall not take any position with respect to, or compromise or settle, such Action
in any way that is reasonably likely to directly and adversely affect the scope, validity or enforceability of the Licensed Patent
Rights without SUBLICENSOR’S prior written consent, which consent shall not be unreasonably withheld. SUBLICENSOR shall incur
no liability to ILDONG as a consequence of such Action or any unfavorable decision resulting therefrom, including any decision
holding any such claim invalid, not infringed or unenforceable. All costs, including, without limitation, attorneys’ fees,
relating to such legal proceedings or other action shall be borne by ILDONG.

 

    	41

    	 

    

 

 

(iv)        Joint
Patent Rights. In the event of an Infringement of a Joint Patent Right, the Parties shall enter into good faith discussions
as to whether and how to eliminate the Infringement. Subject to the foregoing, (A) ILDONG shall have the first right and option
to eliminate such Infringement by reasonable steps, which may include the institution of legal proceedings or other action and
(B) all costs, including without limitation attorneys’ fees, relating to such legal proceedings or other action shall be
borne by ILDONG. If ILDONG does not take or initiate commercially reasonable steps to eliminate the Infringement within one hundred
twenty (120) days from any Infringement Notice, then SUBLICENSOR shall have the right an option to do so at its expense.

 

(b)          Right
to Representation. Each Party shall have the right to participate and be represented by counsel that it selects, in any Action
instituted under Section 10.2.1(a)(ii), (iii) or (iv) by the other Party. If a Party with the right to initiate an Action under
Section 10.2.1(a) to eliminate an Infringement lacks standing to do so and the other Party has standing to initiate such Action,
then the Party with the right to initiate an Action under Section 10.2.1(a) may name the other Party as plaintiff in such Action
or may require the Party with standing to initiate such Action at the expense of the other Party.

 

(c)          Cooperation.
In any Action instituted under this Section 10.2.1, the Parties shall cooperate with and assist each other in all reasonable respects.
Upon the reasonable request of the Party instituting such Action, the other Party shall join such Action and shall be represented
using counsel of its own choice, at the requesting Party’s expense.

 

(d)                             Allocation
of Proceeds. Any amounts recovered by either Party pursuant to Actions under Sections 10.2.1(a)(ii), (iii) or (iv) with respect
to any Infringement, whether by settlement or judgment, shall, after reimbursing ILDONG and SUBLICENSOR for their respective reasonable
out-of-pocket expenses incurred in pursuing such Action and obtaining such recovery (which amounts shall be allocated pro rata
if insufficient to cover the totality of such expenses) be retained by or paid to ILDONG and treated as Net Sales of the Product
affected by the Infringement and for purposes of this Agreement, such that ILDONG shall pay to SUBLICENSOR the applicable royalty
due on such Net Sales pursuant to Section 7.3.1.

 

10.2.2      Defense
of Claims.

 

(a)          Notice.
In the event that any action, suit or proceeding is brought against either Party or any Affiliate of either Party or any Sublicensee
or Distributor of ILDONG alleging the infringement of the Technology or Patent Rights of a Third Party by reason of or the Development
or Commercialization, including the Manufacture, use or sale, of any Compound or Product, by or on behalf of ILDONG, its Affiliates,
Sublicensees or Distributors, such Party shall notify the other Party within five (5) days of the earlier of (i) receipt of service
of process in such action, suit or proceeding, or (ii) the date such Party becomes aware that such action, suit or proceeding has
been instituted and the Patent Coordinators shall meet as soon as possible to discuss the overall strategy for defense of such
matter.

 

    	42

    	 

    

 

(b)          Prosecution
of Infringement claims in the Territory. Except as unanimously agreed by the Patent Coordinators and subject to Article
14, (i) SUBLICENSOR shall have the primary right but not the obligation to institute and control such action, suit or proceeding
in its own name and at its sole expense and in such case, SUBLICENSOR and/or any of its Affiliates shall have the right to separate
counsel at its own expense in any such action, suit or proceeding and, ILDONG shall cooperate with SUBLICENSOR in all reasonable
respects in any such action, suit or proceeding ; (ii) in the event SUBLICENSOR waives its primary right as defined in (i) the
Parties may elect, without being obliged, to jointly commence an action, and in this respect shall be represented by a counsel
jointly chosen by the Parties, decide on a course of action, and share equally in the costs and expenses, and in the amounts recovered
in accordance with, subject to and within the limits set out in SUBLICENSOR’s Licenses, or (iii) in the event SUBLICENSOR
waives its primary right as defined in (i) ILDONG may defend any action, suit or proceeding in its own name and at its sole expense
and in such case ILDONG and/or any of its Affiliates shall have the right to separate counsel at its own expense in any such action,
suit or proceeding and SUBLICENSOR shall cooperate with ILDONG in all reasonable respects in any such action, suit or proceeding.

 

(c)          Cooperation.
Each Party shall promptly furnish the other Party with a copy of each communication relating to the alleged infringement that is
received by such Party including all documents filed in any litigation. In no event shall either Party settle or otherwise resolve
any such action, suit or proceeding brought against the other Party or any of its Affiliates or sublicensees without the other
Party’s prior written consent.

 

10.2.3           Patent
Term Restoration. The Parties hereto shall cooperate with each other in obtaining patent term restoration or supplemental
protection certificates or their equivalents in any country in the Territory where applicable to Licensed Patent Rights. Such cooperation
shall include diligently and timely conferring and coordinating with respect to such matters to ensure compliance with applicable
filing deadlines, and agreeing on procedures to be followed by the Parties to ensure such compliance. In the event that elections
with respect to obtaining such patent term restoration are to be made, SUBLICENSOR shall have the right to make the election with
respect to Licensed Patent Rights.

 

		10.3	Trademark Prosecution and Registration.

 

SUBLICENSOR shall control
the registration of the Licensed Trademark, to be used with Products in the Territory. SUBLICENSOR shall have the primary right
but not the obligation to take any actions as are required to continue and maintain in full force and effect and enforce and defend
all Licensed Trademarks and registrations thereof, against infringement and misappropriation in the Territory, and shall be solely
responsible for all expenses incurred in connection therewith. In the event SUBLICENSOR waives its primary right to take such action,
ILDONG may have the right to take any actions as are required to continue and maintain in full force and effect and enforce and
defend all Licensed Trademarks and registrations thereof, against infringement and misappropriation in the Territory, and shall
be solely responsible for all expenses incurred in connection therewith..

 

    	43

    	 

    

 

11.         TERM
AND TERMINATION

 

11.1      Term.

 

This Agreement shall
commence on the Effective Date and shall continue in full force and effect, unless otherwise terminated pursuant to Section 11.2,
(a) until such time as ILDONG is no longer Developing at least one (1) Compound and/or at least one (1) Product or (b) if, as of
the time ILDONG is no longer Developing at least one (1) Compound and/or at least one (1) Product, ILDONG is Commercializing a
Product, until the expiration of all applicable Royalty Terms with respect to Products under this Agreement (the “Term”).
Upon the expiration of this Agreement as set forth in this Section 11.1, the license rights granted hereunder shall be converted
to perpetual and fully paid-up licenses on Licensed Technology and Licensed Patent Rights, with the right to grant unlimited sublicenses.
However, ILDONG shall continue to pay to SUBLICENSOR royalties on the use of Licensed Trademarks.

 

11.2       Termination.

 

This Agreement may
be terminated by either Party as follows:

 

11.2.1           Unilateral
Right to Terminate Agreement.

 

(a)          SUBLICENSOR
Rights to Terminate for Challenge.  Except to the extent the following is unenforceable under the Applicable Laws of a
particular jurisdiction where a patent application within the Licensed Patent Rights is pending or a patent within the Licensed
Patent Rights is issued, SUBLICENSOR may terminate this Agreement immediately upon written notice to ILDONG in the event that ILDONG
or any of its Affiliates or Sublicenses Challenges any Licensed Patent Rights or assists a Third Party in initiating a Challenge
of any Licensed Patent Rights.

 

11.2.2           Termination
for Breach. Either Party may terminate this Agreement, effective immediately upon written notice to the other Party, for
a material breach (including ILDONG’s failure to meet its diligence requirements and responsibilities as set forth in Section
3; 4 and 5) by the other Party of any term of this Agreement that remains uncured ninety (90) days (sixty (60) days in the event
that the breach is a failure of a Party to make any payment required hereunder) after the non-breaching Party first gives written
notice to the other Party of such breach and its intent to terminate this Agreement if such breach is not cured. For purposes of
clarity, the obligation of the breaching Party to cure any such breach shall be stayed for any time period during which such breach
is the subject of a dispute resolution proceeding pursuant to Section 14.1; provided, that, the obligation of the breaching Party
to cure such breach such breach shall resume commencing on the date of any final resolution of such proceeding.

 

    	44

    	 

    

 

11.2.3           Termination
for Insolvency. In the event that either Party makes an assignment for the benefit of creditors, appoints or suffers appointment
of a receiver or trustee over all or substantially all of its property, files a petition under any bankruptcy or insolvency act
or has any such petition filed against it which is not discharged within sixty (60) days of the filing thereof, then the other
Party may terminate this Agreement effective immediately upon written notice to such Party.

 

11.3       Consequences
of Termination of Agreement.

 

In the event of the
termination of this Agreement pursuant to Section 11.2, the following provisions shall apply, as applicable.

 

11.3.1           Termination
by SUBLICENSOR. If this Agreement is terminated by SUBLICENSOR pursuant to Section 11.2.1, 11.2.2 or 11.2.3:

 

(a)          All
licenses and rights granted by SUBLICENSOR to ILDONG, including all licenses granted to ILDONG pursuant to Section 2.1, shall immediately
terminate.

 

(b)          ILDONG
shall cease to use all Licensed Trademarks, any Marketing Authorization obtained in accordance with the AGREEMENT and shall further
promptly transfer such Marketing Authorizations and/or orphan drug designations to SUBLICENSOR at no cost for SUBLICENSOR..

 

(c)          ILDONG
shall cease to conduct any activity related to the Development and Commercialization of the Product.

 

    	45

    	 

    

 

(d)          Upon
request of SUBLICENSOR, ILDONG shall promptly, and in any event within sixty (90) days after SUBLICENSOR’s request (which
request may specify any or all of the actions in clauses (A) through (H): (A) transfer to SUBLICENSOR all of its right, title and
interest in all Drug Approval Applications and then in its name applicable to the Product, if any, and all Confidential Information
Controlled by ILDONG as of the date of termination relied on by such Drug Approval Applications; (B) notify the applicable Regulatory
Authorities and take any other action reasonably necessary to effect such transfer; (C) provide SUBLICENSOR with copies of all
correspondence between ILDONG and such Regulatory Authorities relating to such Drug Approval Applications; (D) unless expressly
prohibited by any Regulatory Authority, transfer sponsorship and control to SUBLICENSOR of all Clinical Trials of the Product being
conducted as of the effective date of termination and continue to conduct such Clinical Trials after the effective date of termination
to enable such transfer to be completed without interruption of any such Clinical Trial for up to twelve (12) months from the effective
date of termination, except for termination for breach of ILDONG, the fully burdened cost of such continuation to be paid for by
SUBLICENSOR (E) cooperate with SUBLICENSOR, cause its Affiliates to cooperate with SUBLICENSOR and use commercially reasonable
efforts to require any Third Party with which ILDONG has an agreement with respect to the conduct of Clinical Trials for the Product
(including agreements with contract research organizations, clinical sites and investigators), to cooperate with SUBLICENSOR in
order to accomplish the transfer to SUBLICENSOR of similar rights as held by ILDONG under its agreements with such Third Parties;
(F) provide SUBLICENSOR with copies of all reports and Clinical Data generated or obtained by ILDONG or its Affiliates, and all
Promotional Materials used by ILDONG, pursuant to this Agreement that relate to the Product that have not previously been provided
to SUBLICENSOR and provide SUBLICENSOR with a right of access, a right of reference and a right to use and incorporate all Clinical
Data, results and information in all Drug Approval Applications then in its name applicable to the commercialization of Product
and all material aspects of Confidential Information Controlled by it as of the date relating to such Drug Approval Applications
for SUBLICENSOR to use to seek Regulatory Approvals, Pricing Approvals, or Reimbursement Approvals; (G) provide SUBLICENSOR at
cost with all supplies of Compounds and Products in the possession of ILDONG or any Affiliate or contractor of ILDONG; and (H)
provide SUBLICENSOR with copies of all reports and data generated or obtained by ILDONG or its Affiliates pursuant to this Agreement
that relate to any Product that have not previously been provided to SUBLICENSOR; (I) enter into negotiations with SUBLICENSOR
and agree upon and implement a plan for the orderly transition of Development and Commercialization from ILDONG to SUBLICENSOR
in a manner consistent with Applicable Laws and standards of ethical conduct of human Clinical Trials and will seek to replace
all ILDONG personnel engaged in any Development or Commercialization activities, in each case, as promptly as practicable. In connection
therewith, ILDONG shall be deemed to have granted to SUBLICENSOR an exclusive, fully-paid, royalty-free, irrevocable license, with
the right to grant sublicenses under ILDONG’s interest in Joint Improvements and Joint Patent Rights, for the sole purpose
of using, making, having made, offering for sale, selling, having sold, importing and exporting any Products being Developed and/or
Commercialized by ILDONG as of the effective date of such termination in the Field and in the Territory.

 

(e)          Each
Party shall promptly return all Confidential Information and Proprietary Materials of the other Party that are not subject to a
continuing license hereunder; provided, that, each Party may retain one copy of the Confidential Information of the other Party
in its archives solely for the purpose of establishing the contents thereof and ensuring compliance with its obligations hereunder.

 

(f)          ILDONG
shall promptly return to SUBLICENSOR all raw data and results generated in each such Clinical Trial.

 

SUBLICENSOR agrees that it will not voluntarily
terminate the LFB/GTC Agreement (or allow such agreement to be terminated by the Senior Licensors), unless SUBLICENSOR maintains
its license for the Territory on terms and conditions no less favorable to ILDONG as in this Agreement or makes arrangements for
ILDONG to be granted a direct license from the Senior Licensors with terms and conditions no less favorable to ILDONG as in this
Agreement.

 

    	46

    	 

    

 

(g)          Upon
any termination of this Agreement by SUBLICENSOR, (excluding termination by SUBLICENSOR pursuant to 11.2.2), or upon termination
by ILDONG pursuant to 11.2.2, SUBLICENSOR shall buy back from ILDONG, at the Purchase Price, any unsold, unopened SUBLICENSOR
Products in ILDONG’s possession that have been purchased from SUBLICENSOR which are in marketable condition (as determined
in the sole discretion of SUBLICENSOR) and are of a product designation then included in the products being offered for sales
by SUBLICENSOR. The aggregate amount to be paid to ILDONG under this provision may be offset by SUBLICENSOR against claims it
has against ILDONG, including payment of goods supplied under this Agreement. In order to ensure the marketable condition of such
Products, all documentation must be presented indicating proper storage, handling, and shipment of such Products at all times
while in possession by ILDONG. Additionally, and at ILDONG’S sole expense, SUBLICENSOR may request a sample of such Product
be analyzed by an independent laboratory (to be agreed upon by both Parties), to assess the Product’s marketable condition
and adherence to product specifications. In the case that such Product is determined not to be in marketable condition, SUBLICENSOR
will not be obligated to purchase back such Product from ILDONG.

 

11.3.2           Termination
by ILDONG. If this Agreement is terminated by ILDONG pursuant to Section, 11.2.2 or 11.2.3:

 

(a)          At
ILDONG’s election, all licenses granted by SUBLICENSOR to ILDONG pursuant to Section 2.1 shall survive such termination,
in each case subject to ILDONG’s continued payment of all milestone, royalty and other payments under and in accordance with
this Agreement with respect thereto.

 

(b)          Each
Party shall promptly return all Confidential Information and Proprietary Materials of the other Party that are not subject to a
continuing license hereunder; provided, that, each Party may retain one copy of the Confidential Information of the other Party
in its archives solely for the purpose of establishing the contents thereof and ensuring compliance with its obligations hereunder.

 

(c)          ILDONG
shall promptly return to SUBLICENSOR all raw data and results generated in each such Clinical Trial.

 

		11.4	Surviving Provisions.

 

Termination or expiration
of this Agreement for any reason shall be without prejudice to:

 

(a)          Survival
of rights specifically stated in this Agreement to survive, including without limitation as set forth in Section 11.3;

 

(b)          The
rights and obligations of the Parties provided in Sections 8, 9, 10, 12, 13, 14.1 and 14.2 (including all other Sections or Articles
referenced in any such Section or Article), all of which shall survive such termination except as provided in this Article 10;
and

 

(c)          Any
other rights or remedies provided at law or equity which either Party may otherwise have.

 

    	47

    	 

    

 

12.         REPRESENTATIONS
AND WARRANTIES 

 

12.1         Mutual
Representations and Warranties. 

 

SUBLICENSOR and
ILDONG each hereby represent and warrant to the other, as of the Effective Date, as follows:

 

12.1.1           Organization.
It is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization,
and has all requisite power and authority, corporate or otherwise, to execute, deliver and perform this Agreement.

 

12.1.2           Authorization.
The execution and delivery of this Agreement and the performance by it of the transactions contemplated hereby have been duly authorized
by all necessary corporate action and will not violate (a) such Party’s certificate of incorporation or bylaws (or equivalent
charter or organizational documents), (b) any agreement, instrument or contractual obligation to which such Party is bound in any
material respect, (c) any requirement of any Applicable Laws, or (d) any order, writ, judgment, injunction, decree, determination
or award of any court or governmental agency presently in effect applicable to such Party.

 

12.1.3           Binding
Agreement. This Agreement is a legal, valid and binding obligation of such Party enforceable against it in accordance with
its terms and conditions.

 

12.1.4           No
Inconsistent Obligation. It is not under any obligation, contractual or otherwise, to any Person that conflicts with or
is inconsistent in any respect with the terms of this Agreement or that would impede the diligent and complete fulfillment of its
obligations hereunder.

 

12.1.5           No
Government Authorization Required. No government authorization, consent, approval, license, exemption of or filing or registration
with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any
Applicable Laws currently in effect, is or will be necessary for, or in connection with, the transactions contemplated by this
Agreement, or for the performance by it of its obligations under this Agreement.

 

12.1.6           ILDONG
represents and warrants that it has all necessary financial and human resources to enter and perform all its commitments and obligations
contained in the Agreement.

 

12.2         Additional
Representations of SUBLICENSOR.

 

SUBLICENSOR further
represents and warrants to ILDONG, as of the Effective Date, as follows:

 

12.2.1           Validity
of Patent Rights. All Licensed Patent Rights listed on Schedule 4 are existing and, to SUBLICENSOR’ Knowledge,
no issued patents which are part of the Licensed Patent Rights listed on Schedule 4 are invalid or unenforceable.

 

    	48

    	 

    

 

12.2.2           No
Claims.  There are no claims, judgments or settlements against SUBLICENSOR pending, or to SUBLICENSOR’ Knowledge,
threatened, that invalidate or seek to invalidate the Licensed Patent Rights. There is no litigation pending against SUBLICENSOR
or any Affiliate of SUBLICENSOR that alleges that any of SUBLICENSOR’ activities relating to the Compound have violated,
or by Developing the Compound would violate, any of the intellectual property rights of any Third Party (nor has it received any
written communication threatening such litigation). To SUBLICENSOR’ Knowledge, no litigation has been threatened against
SUBLICENSOR or any Affiliate of SUBLICENSOR which alleges that any of its activities relating to the Compound have violated, or
by Developing the Compound would violate, any of the intellectual property rights of any Third Party.

 

12.2.3           No
License. SUBLICENSOR has not previously entered into any agreement pursuant to which it granted a license with respect
to the Compound, or Product or under the Licensed Patent Rights or Licensed Technology to any Affiliate or Third Party, which license
grant remains in effect or which agreement has surviving license rights, or other surviving terms, that are inconsistent with the
rights and licenses granted to ILDONG under this Agreement.

 

12.2.4           Third
Party Patents.  Except the patents disclosed during ILDONG’S due diligence and to SUBLICENSOR’ Knowledge,
no Patent Rights owned or controlled by any Third Party would be infringed by the Development, Manufacture, use of Commercialization
by or on behalf of ILDONG of the Compound or any Product pursuant to this Agreement.

 

12.2.5           No
Interference. To SUBLICENSOR’S Knowledge, (a) the Licensed Patent Rights are not the subject of any interference
proceeding and (b) there is no pending or threatened action, suit, proceeding or claim by any Third Party challenging SUBLICENSOR’S
ownership rights in, or the validity or scope of, the Licensed Patent Rights.

 

12.3         Additional
Representations of ILDONG.

 

ILDONG further represents
and warrants to SUBLICENSOR, as of the Effective Date, as follows:

 

12.3.1           No
Claims.  There is no litigation pending against ILDONG or any Affiliate of ILDONG that relates, directly or indirectly,
to the subject matter of this Agreement and that alleges that any of ILDONG’s activities to be conducted relating to the
Development of the Compound would violate any of the intellectual property rights of any Third Party (nor has it received any written
communication threatening such litigation).

 

12.3.2           Compliance
with Applicable Laws.  ILDONG is in compliance with all Applicable Laws, and is not in default under or in
violation of any Applicable Laws, that, in any case, would reasonably be expected to adversely affect the ability of ILDONG to
comply with and perform its obligations under this Agreement.

 

    	49

    	 

    

 

12.3.3           Electronic
Dataroom. ILDONG represents and warrants that it has been granted access to an electronic dataroom organized by SUBLICENSOR
and therefore has a clear and perfect knowledge and a good understanding of all documents, information and data contained in such
electronic dataroom, and their consequences on rights granted by LICENCOR under the Agreement. Within thirty (30) days of the date
hereof, SUBLICENSOR will use Commercially Reasonable Efforts to transfer a copy of the contents of the electronic dataroom in their
original format to ILDONG and will transfer such other manifestations of the Licensed Technology useful or necessary for ILDONG
to Develop and Commercialize the Products, including without limitation raw data and results generated in each clinical trial and
pre-clinical studies  previously conducted and batch reports from manufacturing runs through the date hereof, to the extent
not included in the dataroom.  On and after the date hereof, SUBLICENSOR will use Commercially Reasonable Efforts to forward
such manifestations of the Licensed Technology that it has in its possession to ILDONG on a regular basis or upon request.

 

13.         INDEMNIFICATION;
INSURANCE

 

13.1         Indemnification
of SUBLICENSOR by ILDONG.

 

ILDONG shall indemnify,
defend and hold harmless SUBLICENSOR, its Affiliates, their respective directors, officers, employees and agents, and their respective
successors, heirs and assigns (collectively, the “SUBLICENSOR Indemnities”), against all liabilities, damages,
losses and expenses (including, without limitation, reasonable attorneys’ fees and expenses of litigation) (collectively,
“Losses”) incurred by or imposed upon SUBLICENSOR Indemnities, or any of them, as a direct result of claims,
suits, actions, demands or judgments of Third Parties, including, without limitation, personal injury and product liability claims
(collectively, “Claims”), arising out of (a) the Development, testing, sale, offer for sale, or Commercialization
by ILDONG or any of its Affiliates, Sublicensees or Distributors of any Product; (b) any breach of this Agreement by ILDONG or
any of its Affiliates, Sublicensees, Distributors or agents; and (c) the gross negligence or willful misconduct of any ILDONG Indemnity
or Sublicensee of ILDONG; excluding, in each of (a), (b) and (c) above, any Claim or Loss with respect to which SUBLICENSOR has
an obligation to indemnify ILDONG Indemnities pursuant to Section 13.2, as to which Claim or Loss each Party will indemnify the
other to the extent of their respective liability for such Loss (unless such Claim or Loss is otherwise expressly excluded from
a Party’s indemnification obligations under this Agreement).

 

		13.2	Indemnification of ILDONG by SUBLICENSOR.

 

SUBLICENSOR shall indemnify,
defend and hold harmless ILDONG, its Affiliates, their respective directors, officers, employees and agents, and their respective
successors, heirs and assigns (collectively, the “ILDONG Indemnities”), against all Losses (including, without
limitation, reasonable attorneys’ fees and expenses of litigation) incurred by or imposed upon the ILDONG Indemnities, or
any of them, as a direct result of Claims arising out of (a) the commercialization by SUBLICENSOR of any SUBLICENSOR Commercialization
Product in the SUBLICENSOR Commercialization Territory following exercise of SUBLICENSOR commercialization option (b) any breach
of this Agreement by SUBLICENSOR or any of its Affiliates, (sub)licensees, distributors or agents; or (c) the gross negligence
or willful misconduct of any SUBLICENSOR Indemnity or (sub)licensee of SUBLICENSOR; excluding, in the case of clauses (a) and (b)
above, any Claim or Loss with respect to which ILDONG or any of its Affiliates has an obligation to indemnify SUBLICENSOR pursuant
to Section 13.1, as to which Claim or Loss each Party will indemnify the other to the extent of their respective liability for
such Loss.

 

    	50

    	 

    

 

13.3         Conditions
to Indemnification.

 

A Person seeking modification
under this Article 13 (the “Indemnified Party”) in respect of a Claim shall give prompt notice of such Claim
to the Party from which indemnification is sought (the “Indemnifying Party”); provided, that, the Indemnifying
Party is not contesting its obligation under this Section 13, shall permit the Indemnifying Party to control any litigation relating
to such Claim and the disposition of such Claim; provided, that, the Indemnifying Party shall (a) act reasonably and in good faith
with respect to all matters relating to the settlement or disposition of such Claim as the settlement or disposition relates to
such Indemnified Party and (b) not settle or otherwise resolve such claim without the prior written consent of such Indemnified
Party (which consent shall not be unreasonably withheld, conditioned or delayed). Each Indemnified Party shall cooperate with the
Indemnifying Party in its defense of any such Claim in all reasonable respects and shall have the right to be present in person
or through counsel at all legal proceedings with respect to such Claim.

 

13.4         Insurance.

 

Not later than thirty
(30) days before the date on which ILDONG or any Affiliate or Sublicensee of ILDONG shall, on a commercial basis, make, use, or
sell any Products, and at all times thereafter until the expiration of all applicable statutes of limitation pertaining to any
such manufacture, marketing, possession, use, sale of other disposition of any Products, ILDONG will, at its expense, and SUBLICENSOR
will, at its expense, with respect to Products, obtain and maintain in full force and effect, comprehensive general liability insurance,
including product liability insurance and Clinical Trial insurance in such amounts as each such Party customarily maintains with
respect to the development, manufacture and sale of its other products. Notwithstanding the foregoing, either Party may elect to
self-insure with respect to any insurance coverage it is required to obtain hereunder as part of a comprehensive self-insurance
program adopted by such Party. For the avoidance of doubt, all insurance obligations and associated costs for any sale and development
of Product within the Territory and over which SUBLICENSOR has little or no control, shall be borne solely by ILDONG.

 

13.5         Warranty
Disclaimer.

 

EXCEPT AS OTHERWISE
EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO ANY KNOW-HOW,
GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND EACH PARTY HEREBY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED,
INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT.

 

    	51

    	 

    

 

13.6         No
Warranty of Success.

 

Nothing contained in
this Agreement shall be construed as a warranty, either express or implied, on the part of either Party that (a) the Development
Program will yield a Product or otherwise be successful or meet its goals, time lines or budgets, or (b) the outcome of the Development
Program will be commercially exploitable in any respect.

 

13.7         Limited
Liability.

 

EXCEPT AS SET FORTH
UNDER SECTIONS 13.1 OR 13.2, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR (I) ANY SPECIAL, PUNITIVE,
INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING, WITHOUT LIMITATION, LOST PROFITS OR LOST REVENUES, OR (II) COST OF PROCUREMENT
OF SUBSTITUTE GOODS, KNOW-HOW OR SERVICES, WHETHER UNDER ANY CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR
EQUITABLE THEORY.

 

14.         MISCELLANEOUS

 

14.1         Disputes;
Consent to Jurisdiction.  

 

The Parties shall use
reasonable efforts to settle any Disputed Matter arising from or related to this Agreement or the breach thereof (each, a “Dispute”)
by promptly referring any such dispute to the Executive Officer of each Party. If the Executive Officers are unable to resolve
any Dispute within thirty (30) days of the date on which the Dispute was referred to them for resolution, the Dispute shall be
subject to the sole jurisdiction of, and venue in, the U.S. federal courts of competent jurisdiction located within New York, New
York, USA (if available), and otherwise the state courts of competent jurisdiction located within New York, New York, USA. ILDONG
and SUBLICENSOR each irrevocably consent to the jurisdiction of such courts, irrevocably waive any objection based on inconvenience
of forum, and agree that process may be served in the manner provided herein for giving notices or otherwise as allowed by New
York or applicable federal law. Notwithstanding the foregoing, either Party shall have the right, without waiving any right or
remedy available to such Party under this Agreement or otherwise, to seek and obtain from any court of competent jurisdiction any
interim or provisional relief that is necessary or desirable to protect the rights or property of such Party.

 

14.2         Notices.

 

All notices and communications
shall be in writing and delivered personally or by internationally-recognized overnight express courier providing evidence of delivery
or mailed via certified mail, return receipt requested, addressed as follows, or to such other address as may be designated from
time to time:

 

    	52

    	 

    

 

	If to SUBLICENSOR:	TG Biologics, Inc.
	 	787 Seventh Ave., 48th Floor
	 	New York, NY 10019
	 	Attention: Hari Miskin
	 	Tel.:  212-554-4492
	 	Fax:  212-554-4531
	 	 
	 	With a copy to:
	 	Alston & Bird LLP
	 	Attn : Mark McElreath
	 	90 Park Avenue
	 	New York, NY 10016
	 	Tel : 212-210-9595
	 	 
	If to ILDONG:	ILDONG Pharmaceutical Co., Ltd.
	 	 
	 	Attn:  SUNGSANG SEO
	 	Tel:  +82-2-526-3357
	 	Fax:  +82-2-526-3020
	 	 
	 	With a copy to:
	 	BD&Licensing Team
	 	ILDONG PHARMACEUTICAL CO., LTD.
	 	Attention: Dong-young Park
	 	Tel: +82-2-526-3383
	 	Fax: +82-2-526-3020

 

Except as otherwise
expressly provided in this Agreement or mutually agreed in writing, any notice, communication or document (excluding payment) required
to be given or made shall be deemed given or made and effective upon actual receipt or, if earlier, (a) three (3) Business Days
after deposit with an internationally-recognized overnight express courier with charges prepaid, or (b) five (5) Business Days
after mailed by certified, registered or regular mail, postage prepaid, in each case addressed to a Parties at its address stated
above or to such other address as such Party may designate by written notice given in accordance with this Section 14.2.

 

		14.3	Governing Law.

 

This Agreement shall
be governed by and construed in accordance with the laws of the State of Delaware, without regard to the application of
principles of conflicts of law.

 

14.4         Competition
Law.  

 

SUBLICENSOR and ILDONG
agree that nothing in this Agreement shall be interpreted in a way that conflicts with EC Block Exemption No: 418/85 on research
and development agreements, or EC Block Exemption No: 240/96 on technology transfer agreements, as issued by the European Commission
(as these may be amended or replaced from time to time).

  

    	53

    	 

    

 

14.5         Binding
Effect.

 

This Agreement shall
be binding upon and inure to the benefit of the Parties and their respective legal representatives, successors and permitted assigns.

 

14.6         Headings.

 

Section and subsection
headings are inserted for convenience of reference only and do not form a part of this Agreement.

 

14.7         Counterparts.

 

This Agreement may
be executed simultaneously in two or more counterparts, each of which shall be deemed an original and both of which, together,
shall constitute a single agreement.

 

14.8         Amendment;
Waiver.

 

This Agreement may
be amended, modified, superseded or canceled, and any of the terms of this Agreement may be waived, only by a written instrument
executed by each Party or, in the case of waiver, by the Party or Parties waiving compliance. The delay or failure of either Party
at any time or times to require performance of any provisions shall in no manner affect the rights at a later time to enforce the
same. No waiver by either Party of any condition or of the breach of any term contained in this Agreement, whether by conduct,
or otherwise, in any one or more instances, shall be deemed to be, or considered as, a further or continuing waiver of any such
condition or of the breach of such term or any other term of this Agreement.

 

14.9         No
Third Party Beneficiaries.

 

Except as set forth
in Sections 13.1 and 13.2, no Third Party (including, without limitation, employees of either Party) shall have or acquire any
rights by reason of this Agreement.

 

14.10         Purposes
and Scope.

 

The Parties hereto
understand and agree that this relationship is limited to the activities, rights and obligations as set forth in this Agreement.
Nothing in this Agreement shall be construed (a) to create or imply a general partnership between the Parties, (b) to make either
Party the agent of the other for any purpose, (c) to alter, amend, supersede or vitiate any other arrangements between the Parties
with respect to any subject matters not covered hereunder, (d) to give either Party the right to bind the other, (e) to create
any duties or obligations between the Parties except as expressly set forth herein, or (f) to grant any direct or implied licenses
or any other right other than as expressly set forth herein.

 

    	54

    	 

    

 

		14.11	Assignment and Successors.

 

Neither this Agreement nor any obligation
of a Party hereunder may be assigned by either Party without the consent of the other which shall not be unreasonably withheld,
except that each Party may assign this Agreement and the rights, obligations and interests of such Party, (a) in whole or in part,
to any of its Affiliates, or (b) in whole, but not in part, to any purchaser of all of its assets or all of its assets to which
this Agreement relates or shares representing a majority of its common stock voting rights or to any successor corporation resulting
from any merger, consolidation, share exchange or other similar transaction.

 

14.12         Force
Majeure.

 

Neither ILDONG nor
SUBLICENSOR shall be liable for failure of or delay in performing obligations set forth in this Agreement, and neither shall be
deemed in breach of its obligations, if such failure or delay is due to a Force Majeure. In event of such Force Majeure, the Party
affected shall use reasonable efforts to cure or overcome the same and resume performance of its obligations hereunder.

 

14.13         Interpretation.

 

The Parties hereto
acknowledge and agree that: (a) each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and
have contributed to its revision; (b) the rule of construction to the effect that any ambiguities are resolved against the drafting
Party shall not be employed in the interpretation of this Agreement; and (c) the terms and provisions of this Agreement shall be
construed fairly as to each Party and not in a favor of or against either Party, regardless of which Party was generally responsible
for the preparation of this Agreement. In addition, unless a context otherwise requires, wherever used, the singular shall include
the plural, the plural the singular, the use of any gender shall be applicable to all genders, the word “or” is used
in the inclusive sense (and/or) and the word “including” is used without limitation and means “including without
limitation”.

 

14.14         Integration;
Severability.

 

This Agreement, and
when executed, the Commercial Supply Agreement(s) set forth the entire agreement with respect to the subject matter hereof and
thereof and supersede all other agreements and understandings between the Parties with respect to such subject matter. If any provision
of this Agreement is or becomes invalid or is ruled invalid by any court of competent jurisdiction or is deemed unenforceable,
it is the intention of the Parties that the remainder of this Agreement shall not be affected.

 

    	55

    	 

    

 

14.15         Further
Assurances.

 

Each of SUBLICENSOR
and ILDONG agrees to duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and
cause to be done such further acts and things, including, without limitation, the filing of such additional assignments, agreements,
documents and instruments, as the other Party may at any time and from time to time reasonably request in connection with this
Agreement or to carry out more effectively the provisions and purposes of, or to better assure and confirm unto such other Party
its rights and remedies under, this Agreement.

 

[Remainder of page intentionally left
blank.]

 

    	56

    	 

    

 

IN WITNESS WHEREOF,
the Parties have caused this Agreement to be executed by their duly authorized representatives.

 

	 	TG BIOLOGICS, INC.
	 	 	 
	 	By:	/s/ Michael S. Weiss
	 	Name: Michael S. Weiss
	 	Title: Executive Chairman, President, & CEO 
	 	 
	 	ILDONG PHARMACEUTICAL CO., LTD. 
	 	 	 
	 	By:	/s/ Jung-chi Lee
	 	Name: Jung-chi Lee
	 	Title: Chairman & CEO

 

    	57

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}]]